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Abstract 
Identifying disease genes from human genome is an important and fundamental 
problem in biomedical research. Despite many publications of machine learning 
methods applied to discover new disease genes, it still remains a challenge because 
of the pleiotropy of genes, the limited number of confirmed disease genes among 
whole genome and the genetic heterogeneity of diseases. Recent approaches have 
applied the concept of ‘guilty by association’ to investigate the association between 
a disease phenotype and its causative genes, which means that candidate genes 
with similar characteristics as known disease genes are more likely to be associated 
with diseases. However, due to the imbalance issues (few genes are experimentally 
confirmed as disease related genes within human genome) in disease gene 
identification, semi-supervised approaches, like label propagation approaches and 
positive-unlabeled learning, are used to identify candidate disease genes via 
making use of unknown genes for training – typically in the scenario of a small 
amount of confirmed disease genes (labeled data) with a large amount of unknown 
genome (unlabeled data). The performance of Disease gene prediction models are 
limited by potential bias of single learning models and incompleteness and noise of 
single biological data sources, therefore ensemble learning models are applied via 
combining multiple diverse biological sources and learning models to obtain better 
predictive performance. In this thesis, we propose three computational models for 
identifying candidate disease genes. 
 vii 
 
1. In this Ph.D thesis, we first propose a computational algorithm Random Walk 
on Protein Complex Network (RWPCN) to prioritize disease genes. Different 
from traditional two-layer phenotype-gene heterogeneous network, the basis of 
RWPCN is a novel three-layer heterogeneous network, where links from 
disease phenotypes to human protein complexes are interacted based on 
confirmed phenotype-gene associations, and links from protein complexes to 
individual proteins are interacted when individual proteins are members of 
protein complexes. To evaluate the performance of the proposed RWPCN, we 
conducted experiments to compare RWPCN with other state-of-art techniques 
and the results show that our RWPCN significantly outperforms existing 
disease gene prediction approaches. In addition, the RWPCN is applied to 
investigate candidate disease protein complexes and predict novel disease 
genes associated with two representative diseases, namely, breast cancer and 
diabetes. 
2. Disease gene identification is a positive-unlabeled problem. Currently, only a 
few disease genes have been identified from large number of unlabeled human 
genome. In the second part of the thesis, we propose a novel disease gene 
classification model, Positive-Unlabeled learning for Disease gene 
Identification (PUDI). Unlike traditional learning models that use unknown 
genes as a negative training set N, PUDI treats unknown genes as an unlabeled 
set U. Since unknown genes may contain unconfirmed disease genes, it is 
inappropriate to label all unknown genes as negative class. Therefore, we 
 viii 
 
design a positive-unlabeled (PU) learning method to partition unlabeled 
training genes into multiple sets and then apply a weighted support vector 
machine (SVM) to build a disease gene classifier. We find that PUDI could 
model the classification problem for disease gene prediction more effectively 
as it achieves significantly better results than the state-of-the-art methods. 
3. Due to inherent complex characteristics of phenotype-gene associations, such 
as pleiotropy of genes and genetic heterogeneity of diseases, disease gene 
identification requires various and sufficient biological data to represent genes 
and reliable computational approaches to build robust classifiers. To further 
improve the performance of disease gene identification, we focus on an 
ensemble positive unlabeled learning model, namely Ensemble 
Positive-Unlabeled learning for disease gene identification (EPU), to combine 
network-based approaches and positive-unlabeled learning in chapter 3. The 
random walk with restart (RWR) algorithm, a network propagation approach, 
is applied to three gene networks to assign combined confidence scores to 
unlabeled genes. Using weighted unlabeled genes and initial labeled genes, we 
build three individual PU learning classifiers to predict ‘soft’ classes for test 
genes. Finally, an ensemble strategy EPU is applied to build an ensemble 
model where individual classifiers’ predictions are linear combined together to 
make final decisions for the test gene class. The experimental results show that 
our proposed EPU is able to produce favorable performance compared to 
state-of-the-art techniques over six disease groups, indicating our ensemble 
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framework could make use of multiple data sources and multiple learning 
models to build an accurate classifier. 
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Chapter 1.  
Introduction 
This chapter begins with a brief introduction of the problem of disease gene 
identification, and then provides the motivation of this research. This is followed by 
a summary of current research contributions and an outline of the PhD thesis. 
1.1  Background 
1.1.1 Motivation and Objective of Disease Gene Identification 
There are more than 2000 monogenic syndromes (the syndromes found associated 
with a single causative gene) in human beings [1]. Each syndrome has a specific 
combination of phenotypic features, which are the biological implementations of 
their underlying genes, and each differs from other syndromes by only one or a few 
of those features [1]. Therefore, discovering phenotype-gene association is a 
fundamental and critical biomedical task, which assists biologists and physicians to 
discover pathogenic mechanism of syndromes. Knowledge of which genes cause 
which disorders will simplify diagnosis of patients and provide insights into the 
functional characteristics of the mutation. 
Disease gene identification is a process by which scientists identify the mutant 
genotypes responsible for an inherited genetic disorder. Mutations in these genes 
can include single nucleotide substitutions, single nucleotide additions/deletions, 
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deletion of the entire gene, and other genetic abnormalities. 
Traditionally, disease gene identification composes of two main steps: genetic 
linkage analysis and positional clone, followed by mutation analysis. Firstly, 
linkage analysis is performed in human pedigrees to detect the susceptible 
chromosome interval that is the approximate location of candidate genes associated 
with diseases [2]. Secondly, the technique ‘positional cloning’ is proposed to 
sequence a set of the candidate genes in the region [3]. This process includes a 
physical mapping and a transcript mapping. From the candidate disease gene set, 
one or more genes can be the real disease gene. Since 1980, positional cloning 
techniques have been used to prioritize candidate genes and these techniques have 
successfully identified disease genes for a number of diseases, such as Duchene 
muscular dystrophy, Huntington’s disease and cystic fibrosis, etc. However, both the 
positional cloning and mutation analysis experiments are labor intensive, tedious 
and time consuming, requiring computational methods to select highly suspicious 
genes for experiment validation. The human genome contains in the range of 20 to 
25 thousand genes. It is a challenging task to identify real disease genes from 
hundreds of candidate genes on the whole genome. To address the challenge, it is 
necessary to prioritize candidate genes from hundreds of experimentally suspicious 
genes using computational techniques, which would greatly reduce the numbers of 
genes for wet-lab experimental analysis. In other words, computational approaches 
help to prioritize the genes, which are likely to associate with disease of interest, for 
further web-lab experiment validation. The common strategy is to rank these 
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candidate genes according to their functional similarity to known disease genes. In 
this thesis, this is called disease gene prioritization. 
1.1.2 Challenges of Disease Gene Identification 
Human genetic disease is a genetic disorder caused by abnormalities in genes or 
chromosomes, especially a condition that is present before birth. Genetic diseases 
are generally divided into two types: single gene disorder and complex disorder.  
A single-gene (monogenic) disorder occurs as a direct result of a single mutation in 
the structure of the DNA, leading to a single basic defect with pathologic 
consequences. Such disorders are passed on to subsequent generations in simple 
patterns according to Mendel’s Laws. As such, these kinds of disorders are often 
called Mendelian disorders [4]. The Mendelian Inheritance in Man (MIM) is a 
comprehensive knowledge base of human genes and genetic disorders. Its Online 
Version, Online Mendelian Inheritance in Man (OMIM) database, currently 
provides information on more than 5000 genetic disorders.  
Genetic disorders may also be multi-factorial, namely complex diseases, which 
reflect the pathologic consequences associated with the effects of a combination of 
genetic mutations, lifestyle and environmental factors, and genetic factors represent 
only part of the phenotypes associated with the disorders [5]. These kinds of 
diseases are called multi-factorial and polygenic (complex) diseases. Out of 5080 
disease phenotypes in OMIM, there are a total of 168 phenotypes associated with 
multiple causative genes in our experiment data which do not obey the standard 
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Mendelian patterns of inheritance [6]. The complex diseases include Alzheimer’s 
disease, asthma, Parkinson’s disease, connective tissue disease, kidney disease, and 
many more. For example, diabetes mellitus type 2, a metabolic disease, is found to 
be associated with multiple gene mutations, and multiple susceptible chromosome 
loci, including chromosomes 2, 3, 4, 5, 6, 7, 13, 15, 17 and 19 [7]. 
In addition, disease gene identification remains a daunting problem due to the 
pleiotropy of genes, the genetic heterogeneity of disease as well as other 
environment factors. Pleiotropy describes the genetic effect of a single gene on 
multiple phenotypic traits. Pleiotropy occurs when one gene influences multiple, 
seemingly unrelated phenotypic traits, such as Phenylketonuria that is a human 
genetic disease that affects multiple systems but is caused by one gene defect. 
Consequently, a mutation in a pleiotropic gene may have an effect on some or all 
traits simultaneously. Contrast to pleiotropy where a single gene may cause multiple 
phenotypic expression or disorders, genetic heterogeneity is a phenomenon in 
which a single phenotype or genetic disorder may be caused by any one of a 
multiple number of alleles or non-allele (locus) mutations. Genetic heterogeneity 
can be classified as either “allelic” or “locus”. Allelic heterogeneity means that 
different mutations within a single gene locus cause the same phenotype expression. 
For example, there are over 1,000 known mutant alleles of the CFTR gene that 
cause cystic fibrosis. Locus heterogeneity means that variations in completely 
unrelated gene loci cause a single disorder. For example, retinitis pigmentosa has 
three origins from autosomal dominant, autosomal recessive and X-linked. 
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Recent approaches are strive to discover the patters of pleiotropy of genes as well as 
the multi factors of genetic disorders using the gene sequences, gene expression and 
PPI network based on the assumption that similar disease phenotypes are caused by 
similar genes in terms of sequence, expression profile similarity and network 
topology. However, above methods merely focus on views of single genes. As genes 
cannot function alone, they are likely to form “functional modules”, where genes 
are likely to attached together to perform a biological function or process. This kind 
of “module” can be protein complex, pathway or metabolic network [8] [9] [10] [11] 
[12] [13]. 
1.1.3 Modular Nature of Genetic Diseases 
It is shown that similar phenotypes are caused by functionally related genes. 
Evidence from many sources suggests that genetically heterogeneous diseases [14] 
[15] (such as Fanconi anemia [16], breast cancer [5] [17] and diabetes [18]) are 
caused by many genes which work together in a single biological module. Such 
module can be a multi-protein complex, or a pathway. For example, it is now 
becoming clear that protein interactions play a key role in the mechanisms of 
cellular functions at the molecular level and determine the outcomes of biological 
processes [19], such as signal transduction, enzyme-mediated metabolism, DNA 
replication and transcription [20]. From the analysis above, the modular nature of 
human genetic diseases could indicate or reflect the modularity in true biological 
interaction networks. 
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Typically, multiple syndromes can be caused by mutations in the same genes, and a 
single disorder can be caused by mutations in different genes. Different alleles of 
genes in different individuals integrate differently with each other to create 
individual final phenotypes [10]. This is the basis of human phenotypic diversity 
and an important factor contributing to the fact that no two individuals are identical. 
For instance, genes involved in the same protein complex or biochemical pathway 
work together to perform specific biological functions. While there is a tendency for 
similar disease phenotypes to be caused by functionally related genes, mutations 
that affect different functions of a pleiotropic gene can result in different phenotypic 
manifestations. As shown in Fig. 1.1, the similar phenotypes of Stickler, Marshall 
and oto-spondylo-mega-epophyseal dysplasia (OSMED) syndromes are caused by 
mutations in the functionally closely related genes COL2A1, COL11A1 and 
COL11A2. The phenotypically distinct Pallister-Hall syndrome is caused by 
mutations in the functionally unrelated or only weakly related GLI3 gene. Several 
genes can underlie one phenotype, as in the case of Stickler syndrome, which can be 
caused by mutations in each of the three collagen genes. Conversely, one gene can 
lead to different phenotypes as in the case of COL11A1 (Stickler and Marshall 
phenotypes) and COL11A2 (Stickler and OSMED phenotypes). The thickness of 
black lines linking genes indicates the (hypothetical) degree of functional 
relatedness between them.  
Although complex disorders are likely to form functional modules, they do not have 
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a clear-cut pattern of inheritance (such as the pleiotropy of genes), which makes it 
more difficult to determine their characteristics than single-gene (Mendelian) 
disorders. In addition, the functional modules, such as protein complexes, have 
temporal dynamics characteristics – structure of functional module may vary with 
“time” in terms of cell cycle phase. Finally, there are no literatures to tell how to 
establish association of functional modules to disease phenotypes. 
 
Figure 1.1: Possible relationships between genes and phenotypes, taken from [10]. 
1.2 Related Prior Works 
Uncovering the associations between genetic diseases and their causative genes is 
one of the fundamental objectives of human genetics [21] due to its significant 
impact in healthcare. 
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Gene association could represent that genes have physically interaction in the 
protein-protein interaction network or have similar/relevant biological functions in 
terms of gene ontology. The recent approaches have applied protein-protein 
interaction (PPI) to detect the association between disease and candidate genes in 
the PPI network [22] [23] [24] [25]. The underlying assumption in these studies is 
that the interacting partners of a disease-causing gene (or more precisely, its gene 
product protein) in the PPI network are likely to cause either the same or similar 
diseases [26]. In order to find similar diseases, some of the existing methods 
compute the similarities between the phenotypes, generating a phenotypically 
similarity network where two phenotypes are linked if they are phenotypic similar. 
These methods first construct a protein interaction network and subsequently 
compute the closeness between candidate genes and known disease genes based on 
network topological information. In particular, Wu et al. [27] built a regression 
model measuring the correlation between phenotype similarity and gene closeness 
in the PPI network for prioritizing candidate disease genes. Vanunu et al. [28] and 
Li et al. [22] designed a global network-based method by formulating constraints on 
the genes’ score function that smooth over the whole network. However, these 
methods only focus on protein-level function prediction. Moreover, proteins cannot 
function isolate; they are more likely to be attached together as functional modules 
(such as protein complexes and pathways) to perform biological functions. Recently, 
Lage et al. assigned a candidate gene to protein complexes and then applied a 
Bayesian model to rank the candidate protein complexes with confidence scores to 
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disease phenotypes [29]. However, they simply assembled those neighboring 
proteins as complexes. Given that protein complexes are molecular groups of 
proteins that work together as ‘protein machines’ for common biological functions, 
only those tight-knit substructures in PPI networks correspond to actual protein 
complexes [30]. As such, the protein complexes constructed were not accurate. 
Additionally, they have not considered the associations among individual protein 
complexes even though many complexes share common/pleiotropic proteins and 
the proteins from different complexes do interact with each other. Biologically, 
genes associated with similar disorders demonstrate a higher probability of physical 
interactions between their gene products [31] [1]. As such, if two protein complexes 
share common proteins or have physical interactions between them, then the 
mutations of certain genes in a protein complex could lead to identical or similar 
phenotypes of its connected protein complexes [1] since the mutations could 
potentially disrupt these complexes’ functions. In this thesis, we believe that 
constructing a protein complex network where nodes are individual complexes and 
the interactions between two complexes are measured by the connection strength 
between them would be a proper model for disease gene prioritization. 
It should be noted that the above methods only provide a gene rank list and a 
threshold is needed to decide whether a specific gene is disease related or not. A 
more biologically meaningful approach would build a binary classification model 
that can automatically identify a gene as disease or not, according to various 
features of biological datasets, such as protein sequence, PPI and gene expression. 
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To address this problem, Lopez Bigas and Ouzounis [32] investigated the 
distinguishing features of protein sequences between disease and non-disease genes. 
Adie et al. [33] further improved on this method by employing a decision tree 
algorithm based on a variety of genomic and evolutionary features (such as coding 
sequence length, evolutionary conservation and presence). In particular, Xu et al. 
[34] employed the K-nearest neighbor (KNN) classifier to predict disease genes 
based on the topological features in PPI networks, including protein degree and the 
percentage of disease genes in the protein neighborhood (the proteins directly 
linking to disease-related proteins). Smalter et al. [35] applied the support vector 
machines (SVMs) classifier using PPI topological features, sequence-derived 
features, evolutionary age features, etc. The above works employ machine learning 
methods to build a binary classifier by using the confirmed disease genes as positive 
training set P and some unknown genes as the negative training set N. However, the 
negative set N will contain unconfirmed disease genes (false negatives), which 
confuses the machine learning techniques for building accurate classifiers. As such, 
the classifiers built based on the positive set P and noisy negative set N do not 
perform as well as they should in identifying new disease genes. To address this 
issue, Mordelet et al. proposed a bagging method ProDiGe for disease gene 
prediction. This method iteratively chooses random subsets (RS) from U and trains 
multiple classifiers using bias SVM to discriminate P from each subset RS. It then 
aggregates all the classifiers to generate the final classifier [36]. However, as the 
random subsets RS from U could still contain unknown disease genes, selecting 
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candidate disease genes and reliable non-disease genes could be helpful for building 
an accurate classification model. In this thesis, we design a novel PU learning 
algorithm to build a more accurate classifier based on P and U [37] [38] [39]. 
The above recent approaches only use a single learning model (such as SVM in 
Smalter et al. [35], KNN in Xu et al. [34]) or single biological datasets (PPI network 
in Xu et al. [34] and protein sequence in Lopez Bigas and Ouzounis [32]) to 
prioritize candidate disease genes from the unlabeled gene set. A classification 
model built on single datasets may be limited by incompleteness and noise of single 
biological datasets. For a classification model built on a single hypothesis, it is not 
easy to achieve competitive performance on all disease groups. To address the 
above issue, an ensemble-based approach is applied to build a combined classifier 
by integrating multiple learning models that could be obtained from any of the 
constituent models [40] [41], such as boosting and bootstrap aggregation (bagging). 
In this thesis, we investigate how to integrate multiple biological datasets and 
learning models to identify disease genes based on the disease gene set and 
unlabeled gene set. 
1.3  Major Contributions and Organization 
As mentioned earlier, the ultimate goal of this research is to prioritize candidate 
disease genes from hundreds of candidate genes on the whole genome. In this thesis, 
this is done through introducing reliable biological modules, especially protein 
complex, applying PU learning algorithm on imbalance genetic dataset, and 
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combining reliable PU learning approaches and various biological datasets. We 
describe a set of novel disease gene prediction models, where efficiencies are 
verified by different disease groups. Our computational tools are following the 
‘Guilt-by-association’ rules that exploit the underlying modularity of disease 
phenome, protein interactome and genome. Through providing an effective 
framework for disease gene prediction, we can integrate additional biological and 
computational resources in the future. Figure 1.2 presents a whole schema of our 
three contributions: RWPCN is a network-based model that applied flow 
propagation algorithm on a novel protein complex interaction network, while PUDI 
exploits PU learning techniques for disease-gene identification based on gene 
biological features. Finally, EPU is an ensemble framework that combines the 
RWPCN and PUDI. 
 
Figure 1.2 Overall Schema for Three Contributions 
 A novel complex-based disease gene prediction algorithm, namely RWPCN, is 
different from the existing methods as our network propagation algorithm is 
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operated at the complex level instead of the protein level. We use reliable human 
protein complexes from CORUM, the comprehensive resource of mammalian 
protein complexes, since these protein complexes are curated from the 
biological literatures. To the best of our knowledge, this is the first attempt to 
exploit the biological modularity of the protein complexes, and exploit effect 
protein complexes to disease phenotypes to detect disease genes in an explicit 
way. We construct a novel Protein Complex Network as in our proposed 
methods. Our experimental results show that such an effort is indeed worth the 
while, for the proposed algorithm is able to discover gene-phenotype 
associations more effectively compared to existing state-of-the-art methods. 
This suggests that the protein complex network can reflect the underlying 
modularity in the biological interaction networks better than simple protein 
interaction networks. Our method is also applied to uncover novel candidate 
genes on specific complex genetic diseases. 
 A novel PU learning approach, PUDI, is applied to build a multi-level classifier 
for disease gene prediction. A new feature selection method is introduced to 
identify the discriminating features. A random walk algorithm is applied on the 
gene similarity network to perform a further partitioning of the unlabeled set U 
into multiple training sets for a more refined treatment of U to build the final 
classifier. We found that PUDI could better model the classification problem for 
disease gene prediction as it achieved significantly better results than the 
state-of-the-art methods. In addition, we investigated the efficiency and time 
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complexity of PUDI and other state-of-the-art techniques for disease gene 
prediction and showed the time spent by each method. Given that many 
machine learning problems in biomedical research involve positive and 
unlabeled data instead of negative data, we believe that the performance of 
machine learning methods for these problems can potentially be improved 
further by adopting a PU learning approach, as we have done here for disease 
gene identification. For future work, we will consider integrating more 
biological resources, such as gene expression data. In addition, we may explore 
more complicated machine learning methods to better model the positive and 
unlabeled data distributions. 
 A novel ensemble positive-unlabeled learning approach EPU is applied to 
identify disease genes. Firstly we perform the random walk with restart 
algorithm on three networks (protein interaction network, gene expression 
similarity network and GO similarity network) to extract multiple positive and 
negative samples from the unlabeled set U. Then we exploit these extracted 
positive and negative samples as training data to build three independent PU 
learning models. Finally, we design a novel ensemble strategy EPU by 
minimizing the overall error rate and giving different weights to different PU 
learning models. We have compared EPU with various state-of-the-art 
techniques. The experimental results show that EPU outperforms the existing 
methods significantly in identifying the disease genes on six disease groups. 
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1.4  Outline 
The PhD thesis is organized as follows: 
Chapter 1 begins with a brief introduction of the basics of human genetic disease 
and the problem of candidate gene prioritization, followed by the motivation of the 
research, with an outline of our work and what it has achieved. 
Chapter 2 provides a survey on the literatures relevant to this topic, including 
prioritization algorithms on single data sources and integration algorithms on 
multiple sources. 
Chapter 3 introduces the protein complex network model. We propose a random 
walk method on this model that integrates the protein-protein interaction network 
and protein complex information for disease gene prioritization. 
Chapter 4 focuses on the positive unlabeled learning algorithm for disease gene 
identification. We conduct the experiments to compare our PUDI with several 
state-of-the-art techniques in general disease genes and specific disease classes, and 
investigate the capacity of PUDI to identify novel disease genes. 
Chapter 5 proposes a novel ensemble framework, EPU, to identify disease genes in 
six disease classes. The predicted novel candidate genes for metabolic and cancer 
diseases are shown in this part. 
Finally, Chapter 6 concludes this thesis and presents possible directions to extend 
the current scope of this entire PhD research. 
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Chapter 2.  
Literature Review 
Disease gene identification is a process to detect the mutant genotypes that cause a 
corresponding genetic disorder. Mutations in these genes are mainly divided into 
three conditions: 1. Single nucleotide substitution/additions/deletions; 2. Deletion of 
the entire gene; 3. Other genetic abnormalities. Disease gene identification follows 
two procedures: first DNA is collected from several patients who suffer same 
genetic disease; then DNA samples are screened to determine regions where the 
mutations could reside [2]. Genes in this region (more than 10 Mb) are called 
candidate genes, one or more of which might be the real disease gene. Identification 
of the most probable of these candidate disease genes for further wet-lab 
experimental analysis is a significant challenge because the number of genes in the 
region is in the range of dozens, or even hundreds. Identification of all the genes in 
the region is time-consuming and expensive. The common strategy is to rank these 
candidate genes according to their functional similarity to known disease genes, and 
then to prioritize top ranked candidate genes as novel disease genes. A number of 
computational methods have been developed to address this problem. In this chapter, 
we provide a comprehensive survey on disease gene discovery methods using 
various biological data sources and computational strategies that combine multiple 
data sources and learning methods. 
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2.1 Prioritization of Candidate Genes Based on Biological 
Data Source 
In this section, we introduce disease gene discovery methods based on different 
biological data sources, including sequence-based methods, gene expression based 
methods, ontology-based methods, and Protein-Protein Interaction (PPI) network 
based methods. 
2.1.1  Sequence-Based Methods 
A protein is involved in a genetic disease when its corresponding gene is mutated, 
impairing its function or expression strongly enough to produce one or several 
abnormal phenotypes (called disease phenotypes). With the completion of the 
human genome sequence project, there is an opportunity to investigate disease 
susceptibility loci on a large scale (genome size of Homo sapiens: 3.2 Gb), in terms 
of the likely or known functions of the annotated genes present within them. Several 
research groups predicted disease genes through sequence-based features, because 
they found that human genes involved in hereditary disease share some common 
distinct sequence characteristics which render them more susceptible to mutations 
causing genetic disorders [42] [43] [32] [33]. 
Lopez-Bigas et al. [32] investigated some features of protein sequences between 
disease genes and non-disease genes. They found that proteins involved in 
hereditary diseases tend to be long, with highly conserved amino acid sequences, 
wide phylogenetic extent, and without similar paralogues. Adie, Adams et al. [33] 
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found 24 sequence-based features, which were significant differences between 
disease genes and unknown genes. For example, disease genes have a significantly 
larger number of cDNA length and encoded larger proteins, significantly longer 3’ 
UTR, and longer distance to the nearest neighboring genes. Based on these features, 
they created an automatic classifier using the decision tree algorithm which 
typically produces a tree that is predictive, concise and easy to understand. It is 
called PROSPECTR, which ranks genes in the order of likelihood of involvement in 
diseases. 
2.1.2  Gene Expression Based Methods 
Gene expression measurements on a genome-scale, representing the transcriptome, 
have been accomplished through the technological advancement of microarrays. 
Since genes involved in identical functions tend to show very similar expression 
profiles, co-expression analysis could be a powerful approach for inferring 
functional relationships which may correlate with similar disease phenotypes [44] 
[45]. Genes that are co-expressed tend to be involved in the same biological 
processes. Co-expression between genes is usually calculated based on the 
microarray data. However the microarray data is noisy, therefore co-expression does 
not strongly suggest a functional relation. Conserved co-expression could be a much 
stronger criterion than single species co-expression to the genes relevant to similar 
disease phenotypes, because significant co-expression existing in more than one 
species (more orthologous) indicates the significance and stability of the 
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relationship in evolutionary history [46]. Ala et al. [47] showed that reliable 
disease-relevant relationships may be identified from massive microarray datasets 
by concentrating only on genes sharing similar expression profiles in both humans 
and mice. Integration of human-mouse conserved expression with a phenotype 
similarity map systematically allows the efficient identification of disease genes in 
large genomic regions. Combining evolutionarily distant species to calculate 
evolutionary co-expression will further increase the reliability. Oti et al. [48] used 
co-expression data from yeast (S. cerevisiae), nematode worms (C. elegans), fruit 
flies (D. melanogaster), mice (Mus musculus) and humans (homo species), and the 
co-expression predictive value could be improved using evolutionary conservation. 
Figure 2.1 illustrates the method of calculating conserved co-expression between 
humans and flies involving KOG0011 and KOG3438, which are defined by the 
eukaryotic clusters of the Orthologous Groups (KOG) database. KOG0011 contains 
two genes in humans (RAD23A and RAD23B) and flies (FBgn0026777 and 
FBgn0039147) while KOG3438 contains one in humans (CKS1B) and two in flies 
(FBgn0010314 and FBgn0037613). For one species, the KOG0011-KIG3438 
co-expression score is computed as the mean of all gene-gene correlations between 
the two KOGs. The final conserved co-expression correlation between humans and 
flies is calculated by taking the mean of two single species KOG0011-KIG3438 
co-expression values. They found that the evolutionary conservation of 
co-expression between species improved the predictive power of co-expression data 
and was more reliable than co-expression vectors in single species. Microarray 
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signal values were measured by the Spearman Rank Correlation Coefficients (that is 
defined as the Pearson correlation coefficient between the rank variables) as shown 
in the following equation: 
         i i iii ii yyxxyyxx
22
     (1) 
where    and    are the  
   elements of two gene expressions of vector   and 
vector  ,   and   are the means of values of the gene expression vectors   and 
 . The authors took the mean of species-specific KOG-based co-expression scores 
over all species considered. 
 
Figure 2.1: Procedure for calculating conserved co-expression scores 
2.1.3  Ontology-Based Methods 
Ontologies define concepts/terms and their relationships within a specific subject 
area. It is a formal way of representing knowledge in which concepts are described 
by their meanings and their relationships to each other [49]. There are several 
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ontologies in the field of biomedical research, such as Gene Ontology (GO) [50], 
eVOC anatomical ontology [51], mammalian phenotype ontology (MP) [52] and 
human phenotype ontology [53]. Gene Ontology (GO) describes the biological 
process, molecular function and cellular location of action of a protein in a generic 
cell. The eVOC ontologies provide simple sets of controlled terms describing 
human anatomical systems, cell types, diseases and developmental stages. 
Several candidate-gene identification systems that rely on grouping GO terms have 
been reported [54] [55] [56]. Turner et al. [54] proposed an approach called POCUS 
(prioritization of candidate genes using statistics) that prioritizes candidate genes 
across multiple susceptibility loci that share GO terms. Perez-Iratxeta et al. [55] 
developed a methodology based on biomedical literatures that associate 
pathological conditions with particular Gene Ontology (GO) terms, which then 
allow candidate disease genes to be ranked according to the number of these terms 
they share. Freudenberg and Propping [56] produced clusters of known disease 
genes based on a measure of phenotypic similarities that are computed according to 
their phenotypic appearances, using the indices ‘periodicity’, ‘etiology’, ‘tissue’, 
‘age of onset’ and ‘mode of inheritance’. Candidate genes were then scored 
according to the GO terms shared with known disease genes in the clusters. 
Tiffin et al. [57] used another kind of ontology, the eVOC anatomical system 
ontology [51], to predict disease genes. In Figure 2.2, they first identified the 
association between eVOC anatomy terms and disease names according to their 
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co-occurrence in the PubMed literature, and then ranked each term based on the 
frequency of association. Finally, candidate disease genes identified by linkage 
analysis were prioritized based on their corresponding annotation with the selected 
disease-related eVOC terms. 
 
Figure 2.2: Identifying candidate genes using eVOC terms 
2.1.4  PPI Network Based Methods 
Physically interacting proteins tend to be involved in the same cellular process [58]. 
Hence, proteins encoded by genes mutated in inherited genetic disorders are likely 
to interact with proteins known to cause similar disorders, suggesting the existence 
of disease sub-networks [31]. Oti et al. [24] predicted interacting partners of disease 
genes in the PPI network. Xu et al. [34] found that disease genes share some distinct 
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topological features in the PPI network compared to unknown genes. Based on 
these distinguishing features, they employed the K-nearest neighbor classifier to 
predict novel disease genes that are functionally similar to known disease genes. 
Kӧhler et al. [25] used the random walk with restart (RWR) algorithm [59] to 
prioritize candidate genes. In the susceptible region detected by QTL, there are   
genes called candidate genes. Firstly, candidate genes and known disease genes are 
mapped to the PPI network. Then, the disease genes are used as source nodes to run 
the RWR algorithm, and the candidate genes are scored by their proximity to known 
disease genes. Finally, the candidate genes are prioritized based on the proximity 
scores. 
In Figure 2.3, one genetic disease is represented as five phenotypes in the database 
of Online Mendelian Inheritance of Man (OMIM) [60]. The corresponding known 
disease genes are mapped to the PPI network, represented as yellow nodes without 
an integer number. Candidate genes are represented as yellow nodes with a number, 
say, 1, 2 and 3. As shown in Figure 2.3, the third candidate gene is well connected 
to known disease genes; therefore it is very likely to be a real disease gene. After 
running the RWR algorithm, this gene is given the highest proximity score and 
ranked at the top. 
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Figure 2.3: Candidate genes prioritization using random walk with restart (RWR) 
algorithm, taken from [25]. 
2.2 Integration Methodologies on Candidate Genes 
Prioritization 
As more genes are being sequenced and annotated, and gene/protein interaction data 
are accumulating [61] [62], an ever-increasing wealth of biological data is now 
available in public databases. Each data source covers part of the human genome, 
therefore these data sources are complementary to each other. For example, a gene 
that has been extensively studied for a long time will have a large amount of 
associated literature and have a better chance of being annotated in GO [50]. Genes 
that have well-characterized protein products are more likely to be found in the PPI 
network. In this section, we introduce several representative integration algorithms 
on disease gene identification. 
SUSPECTS: Adie et al. [63] proposed a tool named SUSPECTS for the 
prioritization of candidate genes. In this tool, gene annotation, gene expression and 
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protein sequence data are used to prioritize disease candidate genes. Given a set of 
confirmed disease genes associated with a particular disease as the training set, each 
test gene is scored based on four lines of evidence: first by Prospectr [33] on the 
basis of its sequence features; second by the extent of co-expression with the 
training set based on expression data [64]; third by the number of rare (found in <5% 
of all proteins) protein domains, obtained from the Interpro [65] database, shared 
with the training set; and finally by the functional semantic similarity [66] to genes 
in the training set. The four scores are then combined to final scores that are 
weighted depending on the amount of information available for each line of 
evidence. 
This approach relies on good quality functional annotation for each candidate gene. 
Genes that are lacking in the GO, expression and protein domain may limit the 
prediction performance of the method. 
CAESAR: Gaulton et al. [67] integrated data from several ontologies to discover 
disease genes associated with disease phenotypes that are of interest to users. Their 
integration algorithm is called CAESAR. CAESAR requires a user-defined body of 
text (referred to as a corpus) to represent a disease of interest. This corpus is ideally 
an authoritative and comprehensive source of biological knowledge about the 
diseases of interest. It can be the clinical symptom of a disease or an OMIM 
identifier [60]. CAESAR uses the OMIM record as the corpus when an OMIM 
identifier is available.  
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Four ontologies are used in CAESAR, namely the Biological Process (BP) and 
Molecular Function (MF) ontologies (from GO) [50], the mammalian phenotype 
ontology (MP) [52], and the eVOC anatomical ontology [51]. For each ontology, 
CAESAR uses text mining techniques to extract the ontology term and description 
that comprise a document. Each ontology document and the corpus are represented 
as vectors in word space,             , where elements are weighted counts of 
the words within the document. The similarity score of each ontology to the corpus 
is calculated as the Cosine similarity between the ontology vector and corpus vector. 
A score     of gene   for source   is then calculated as either the maximum, sum 
or mean of the disease similarity scores of the matched ontology terms annotating 
gene  . Then the normalized score for each gene is defined as 
  jjijij SvZ          (3) 
where    is the mean and    is the standard deviation of the scores from data 
source  . Finally, the combined score for one candidate gene is obtained by taking 
the maximum, sum or mean of the modified scores     from different data sources. 
Finally, CAESAR may be ineffective for those genes and traits with insufficient 
annotations and text description. To overcome this issue, this method could include 
other data sources, such as functional gene interaction and other species systems.   
PRIORITIZER: Franke et al. [68] proposed a method named Prioritizer to 
discover disease genes from the susceptibility loci. They first compiled a functional 
human gene network that comprises known interactions derived from different 
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databases, i.e., the Kyoto Encyclopedia of Genes and Genomes (KEGG) [69], the 
Biomolecular Interaction Network Database (BIND) [70], Reactome [71], and the 
Human Protein Reference Database (HPRD) [72] using a Bayesian classifier. Then 
they predicted some other functional relationships from GO and microarray data 
using the Bayesian framework, and constructed a human gene functional network. 
Finally, candidate genes were prioritized based on the shortest path distance to 
known disease genes in the functional network. 
This method can be further improved by both the quality of the data sets making up 
gene networks and the efficiency of statistical methods incorporating the networks. 
TOM: Rossi et al. [73] proposed a web-based system called Transcriptomics of 
OMIM (TOM) to predict novel disease genes by integrating gene expression data 
and GO data [50]. They used confirmed disease genes from OMIM [60] as seeds, 
and defined an expression neighborhood (a set of candidate genes with similar 
expression to the seeds). Next, they further filtered candidate genes based on their 
functional annotation in GO, with which they were able to extract the genes 
involved in the same or similar biological processes as the seeds and filter the other 
genes with different biological process. This statistically validated filtering allows 
the targeted extraction of a shortlist of candidate genes, thus saving resources for 
the following costly and time-consuming genetic analysis. However, this method 
may be ineffective for disease genes that are poorly characterized by GO and gene 
expression. 
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Prediction based on Disease Protein Complex Method: Genes sharing mutant 
phenotype are highly correlated in their biological functions [74]. The first work to 
integrate phenotype similarity was proposed by Lage et al. in 2007 [29]. For a 
disease phenotype, they found the most probable candidate genes by finding the 
most probable corresponding protein complexes, which comprised of the candidate 
genes and disease genes associated with similar disease phenotypes. The procedures 
are described in Figure 2.4, using Leber Congenital Amauros (LCA) as an example. 
The first step is to find protein complexes including the candidate genes. The 
protein complexes are named as the candidate complexes. In the second step, 
proteins known to be involved in similar disorders are identified in the candidate 
complexes. In this case, proteins that are involved in different disorders comparable 
to LCA are scored according to the phenotype similarities. The next step involves 
scoring and ranking the candidate complexes using the Bayesian Disease Gene 
Predictor as shown in Equation 4. Finally, the ranking of candidate genes are 
obtained according to their ranking within corresponding candidate complexes. 
               
                        
                         
 
   
    (4) 
where               is the posterior probability that the protein    is the 
disease-related protein after evaluating all the data. The                is the 
probability of obtaining the data if the protein    is disease related. 
However, this method does not use actual protein complexes but simply assembles 
neighboring proteins as complexes (consisting of a protein and all their direct 
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interaction partners). 
 
Figure 2.4: Steps in scoring each candidate in the linkage interval, taken from [29]: 
First, N candidate genes associated with the target disease phenotype (Leber 
congenital amaurois) are found within the linkage interval identified by linkage 
studies. Then, protein complexes including the N candidate genes are virtually 
pulled down. Third, all disease-related proteins in protein complexes are identified 
and are colored based on their phonotypical similarity to the target disease, Leber 
congenital amaurois. Finally, each candidate gene is scored according to phenotypes 
associated with the proteins in the candidate protein complex by the Bayesian 
predictor.   
CIPHER: Wu et al. [27] proposed an integration method called CIPHER, which 
integrates the PPI network and the phenotype information obtained from OMIM. 
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Given a query phenotype and a set of candidate genes, CIPHER calculates a 
concordance score between the query phenotype and the candidate gene as shown 
in Figure 2.5. In the first step, it calculates a similarity profile of the query 
phenotype. The similarity profile is a numerical vector, consisting of the similarity 
scores between the query phenotype and all phenotypes. The similarity score 
between two phenotypes is calculated based on the topological distance between 
two sets of associated disease genes in the PPI network as shown in Equation 5: 
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where Gaussian kernel  
  
   
 
 is used to transfer gene-gene distance to gene-gene 
closeness.    is a constant, and     is the coefficient of this regression model, 
respectively. In the second step, the closeness profile is calculated from a candidate 
gene to all the phenotypes. The closeness profile is a numerical vector, an element 
of which denotes the proximity from the candidate gene to a phenotype. It is 
calculated based on the topological distance between the candidate gene and the set 
of disease genes associated with the phenotype in the PPI network, as shown in 
Equation 6: 
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where     
  is the topological distance of two genes. Finally, a concordance score is 
calculated as the correlation between the similarity profile and closeness profile. 
The candidate genes are ranked based on corresponding concordance scores as 
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shown in Equation 7: 
   )()(, gpgppg SSCOVCS       (7) 
where     and   denote the covariance and standard deviation, respectively. 
However, Wu's method is limited by the consideration of only small localized 
regions in both the protein interaction network and phenotype network. The global 
network analysis may provide ways to interpret the relationships between different 
diseases. 
 
Figure 2.5: Scoring scheme of CIPHER, taken from [27] 
Multiple Kernel Learning: One challenge in computational biology is to integrate 
heterogeneous biological datasets that are derived from various types of 
experimental data. To address this issue, Kernel-based methods are applied to 
represent each data source by means of kernel function, which defines similarities 
between pairs of genes, proteins and so on. Such similarities can be the 
relationships that capture the patterns of the underlying biological characteristics. 
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Therefore, the kernel-based method, Multiple Kernels Learning (MKL), has been 
successfully used to integrate heterogeneous data sources [75]. 
De Bie et al. [76] extended the MKL method to one-class classification problems. 
Similar to Lanckriet et al. [75], they represented each data source (including gene 
expressions, protein sequences and protein interactions) by means of a specific 
kernel matrix, which was called a gene functional similarity matrix   . Different 
kernel functions corresponded to different data sources and interpreted different 
notions of similarity. Then they combined multiple kernels into one in terms of 
linear combination         
 
   . To find the optimal linear discriminant, the 
SVM ranking model was trained based on the combined kernel, using semi-definite 
programming (SDP) [77]. 
RWRH: Li et al. [22] proposed a RWRH (Random Walk with Restart on 
Heterogeneous Network) algorithm to infer the gene-phenotype relationships as 
shown in Figure 2.6. It connects the protein interaction network and the phenotype 
network by gene-phenotype relationships to construct a heterogeneous network. It 
then extends the random walk with restart (RWR) algorithm to the heterogeneous 
network. 
The RWRH algorithm is inspired by the co-ranking framework and ranks 
phenotypes and genes at the same time. It uses this algorithm to disclose the 
relationship between diseases. For one given disease, the disease phenotypes and 
disease genes are used as seed nodes to run the RWRH algorithm. Other phenotypes 
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are ranked based on their relevance to the disease. On the other hand, the top ranked 
genes are used to identify disease associations. In the RWRH algorithm, two data 
sources are complementary to each other and reinforce each other. 
The RWRH algorithm only relies on the protein interaction network and does not 
consider protein complexes, which are viewed as molecular machines that integrate 
multiple gene products to perform biological functions. 
 
Figure 2.6: Illustration of Heterogeneous Network in RWRH, taken from [22]:  
2.3 Summary 
This chapter provides a literature review of the representative computational 
methods on disease gene prioritization, including prioritization algorithms using 
various biological data sources and ensemble strategies to integrate data sources and 
learning models. 
Network propagation methods are exploited to prioritize disease genes based on the 
PPI network and phenotype similarity network [25] [22] [27]. However, these 
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methods only focus on protein-level associations instead of complex-level 
associations. As proteins cannot function isolation, they are more likely to be 
attached together as functional modules (such as protein complexes and pathways) 
to perform biological functions. In Chapter Three, we build protein complex 
network model where nodes are individual complexes and the interactions between 
two complexes are measured by the connection strength between them. The 
experimental results show that the protein complex network model is able to 
discover gene-phenotype associations more effectively than protein-level models. 
It should be noted that the above methods prioritize candidate disease genes based 
on gene rank scores and a threshold is needed to identify whether a specific gene is 
disease related or not. A more biologically meaningful approach would be to build a 
binary classification model that can automatically identify a gene as disease-related 
or not, according to various features of biological datasets, such as protein sequence 
[32] and PPI topological features. However, these machine learning methods 
typically treat the unknown genes as the negative set for building disease gene 
classifiers. Such a kind of classifiers do not perform very well because unknown 
genes may include unconfirmed disease genes. To address this issue, we have 
designed a novel PU learning algorithm in which we treat unknown genes as the 
unlabeled set instead of negative examples, as described in Chapter Four [34].  
In addition, it should be pointed out that the above recent approaches only use a 
single learning model [34] [35] or a single biological dataset [32] [34] to identify 
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candidate disease genes. However, ensemble-based approaches are more robust and 
reliable compared to the classification methods built on single biological datasets 
and learning models. In Chapter Five, we propose a novel ensemble positive 
unlabeled learning model for disease gene identification. The experimental results 
demonstrated that our proposed ensemble method significantly outperforms the 
three component learning models.  
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Chapter 3.  
Predicting Disease Gene via Protein 
Complex Network Propagation 
Recent studies have revealed that proteins associated with similar disease 
phenotypes have high probability of physical interactions between their products. 
And proteins cannot function alone, they are likely to be attached together to 
perform biological functions. In this chapter, we construct a novel human protein 
complex network by integrating human PPI network and CORUM protein 
complexes. We conduct a genome-wide disease gene prioritization for 
multi-factorial diseases using such a human protein complex network. Using our 
approach, the top ranked candidate disease genes that are found to be closely 
associating with protein complex can potentially be used to guide the prediction of 
disease-related protein complexes. 
3.1 Introduction 
Phenotypically similar diseases are found to be caused by functionally related genes, 
suggesting a modular organization of the genetic landscape of human diseases that 
mirrors the modularity observed in biological interaction networks. Protein 
complexes, as molecular machines that integrate multiple products to perform 
biological functions, express the underlying modular organization of protein-protein 
interaction network. As such, protein complexes can be useful for interrogating the 
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networks of phenome and interactome to elucidate gene-phenotype associations of 
diseases. 
We propose a technique called RWPCN (Random Walker on Protein Complex 
Network) for predicting and prioritizing disease genes in this chapter. The basis of 
RWPCN is a protein complex network constructed using existing human protein 
complexes and protein interaction network. To prioritize candidate disease genes for 
the query disease phenotypes, the associations between the protein complexes and 
query phenotypes are computed in their respective protein complex and phenotype 
networks. RWPCN is evaluated on predicting gene-phenotype associations and the 
method is observed to outperform existing approaches. We also apply RWPCN to 
predict novel disease genes for two representative diseases, namely, Breast Cancer 
and Diabetes. 
Our proposed method is different from the existing methods as our network 
propagation algorithm is operated at the complex level instead of the protein level. 
We use reliable human protein complexes from the Comprehensive Resource of 
Mammalian protein complexes [78] since the protein complexes are curated from 
the biological literatures. To the best of our knowledge, this is the first attempt to 
present and exploit the biological modularity of the protein complexes and their 
relationships in an explicit way. 
Guilt-by-association prediction and prioritization of disease genes can be enhanced 
by fully exploiting the underlying modular organizations of both the disease 
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phenome and the protein interactome. As the protein complex network can reflect 
the underlying modularity in the biological interaction networks better than simple 
protein interaction networks, RWPCN is found to be able to detect and prioritize 
disease genes better than traditional approaches that used only protein-phenotype 
associations. 
3.2 Method 
In this section, we will first introduce the overall network structure for RWPCN 
algorithm, which includes the phenotype network, protein complex network, protein 
interaction network, as well as gene-phenotype associations. Then, we describe the 
construction of the phenotype network and protein complex network. With these, 
we then present the RWPCN algorithm to prioritize disease-related genes. 
3.2.1  Overall Network Structure in RWPCN 
Figure 3.1 depicts the overall network structure used in RWPCN. It consists of three 
levels of networks, namely, the phenotype network (top), protein complex network 
(middle), and the protein interaction network (bottom). In the phenotype network at 
the top level, we connect phenotypes using K-NN model (K-Nearest Neighbor). In 
Figure 3.1, the links are marked with blue lines, where the thicker lines denote 
higher phenotypic similarities. 
The protein complex network in the middle layer is where phenotypically related 
protein complexes are connected. Within the protein complex networks, the links 
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are marked with gray lines, with the thicker lines indicating stronger linkage 
strengths between the two corresponding protein complexes. We will describe how 
to compute the protein complexes’ linkage strengths later. The links between the 
phenotypes and complexes capture the known gene-phenotype associations, 
denoted by dashed blue lines. 
At the bottom level is the PPI network. Two proteins are connected if they are 
reported to be interacting to each other. Across the networks, each protein complex 
in the middle level links with all its component proteins (yellow nodes) in the PPI 
network. 
Given a query disease phenotype (a query node in the top level), our objective is to 
predict disease genes for this phenotype in the bottom level PPI network, guided by 
the protein complex relationships in the middle level. Our proposed RWPCN 
algorithm will traverse between the three networks and exploit the structural 
relationships accordingly. 
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Figure 3.1 Illustration of the overall network structure in RWPCN 
3.2.2  Constructing Phenotype Network 
Biologists already have a detailed knowledge of the phenotypes that are associated 
with each other. These phenotype associations have been used to prioritize 
candidate disease genes as well as to discover functional relations between genes 
and proteins [74]. 
Phenotype network is constructed using k-NN model (k-Nearest Neighbor). That is, 
for each phenotype pti, we compute its top k most similar phenotypic neighbors (i.e. 
having the k highest phenotypic similarities with pti) to link to it. We experimentally 
test the effects of different values of k on the performance of the proposed 
algorithm, and set k = 10 as the default value. 
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As recommended in [74], similarity values in the range [0, 0.3] are believed to be 
uninformative and noisy while those in [0.6, 1] are considered to be reliable. 
Therefore, we re-compute the phenotypic similarity between     and     using a 
logistic function                 
                   used in [79]. We used the 
default values recommended in [79] for the parameters c and d, namely c = -15 and 
d = log(9999) respectively. 
3.2.3  Constructing Protein Complex Network 
A PPI network (in the bottom level) is an undirected graph GPPI = (VPPI, EPPI), 
where VPPI is the set of nodes (proteins) and E ={(u,v)| u,v∈VPPI}is the set of edges 
(protein interactions). To construct protein complex network in the middle level, we 
need to collect known protein complex data or use some computational methods to 
predict protein complexes. For the former, we use the Comprehensive Resource of 
Mammalian protein complexes (CORUM) database [78], which is a collection of 
high quality experimentally verified mammalian protein complexes. However, the 
CORUM complex database is still far from complete and they are built from 2400 
different genes, covering 12% of protein-coding genes in human [78]. As such, the 
protein complex set COM consists of a set of multi-protein complexes from 
CORUM (set CM) as well as a set of individual complexes (set CI) ─ namely those 
individual proteins that are not involved in any of the current CORUM complexes. 
As such, we have the following: 
COM = CM∪CI,                          (10) 
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CM={cA| cA∈CORUM, cA is a complex}     (11) 
           CI={{p}|  cA∈CORUM, pcA, p∈VPPI}    (12) 
Given the protein complex set COM, the protein complex network is defined as a 
directed super graph GCOM = (VCOM ,ECOM), where the super node set VCOM = COM 
denotes a set of protein complexes and ECOM = {(cA,cB)| cA,cB∈VCOM} represents the 
set of links between protein complexes. Note that a link (cA,cB)∈ECOM can be 
categorized into one of three types depending on the nature of complexes cA and cB, 
namely, EC2C (C2C links between two multi-protein complexes), EI2I (I2I links 
between two individual complexes), and EI2C (I2C links between an individual 
complex and a multi-protein complex). Next, we describe how to assign weight for 
these three types of links.  
Note that each complex cA∈CM is a super node that can be represented as a graph 
cA = (VcA,EcA) where the set VcA represents all the proteins in the complex cA, and the 
set EcA represents the protein-protein interactions among the proteins in VcA. Given 
two complexes cA= (VcA,EcA) and cB= (VcB,EcB), cA,cB∈CM , a C2C link between cA 
and cB, EC2C(cA,cB) can be quantified as follows: 
|)||(|*|)||(|
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       (13) 
where 
   (14) 
1,   if (PA, PB) ∈ EPPI 
0,   Otherwise 
I(PA,PB) = 
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Basically, Equation (13) evaluates how closely the protein members from different 
complexes interact with each other. If there are a lot of physical interactions 
between the members from two complexes (non-overlapping proteins), then the two 
complexes are likely to be highly related as mutations of proteins in one protein 
complex could correspondingly disrupt the function of other complexes, thereby 
producing similar disease phenotypes. Note that according to equation (13), it is 
easy to know that EC2C(cA,cB) = EC2C(cB, cA). 
In the case that we have one multi-protein complex cA∈CM and one individual 
protein complex IA∈CI, then the C2I link EC2I (cA, IA) and the I2C link EI2C (IA, cA) 
can be defined as follows: 
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Finally, given two individual protein complexes IA and IB (IA, IB∈CI), then the I2I 
link EI2I (IA, IB) and the I2I link EI2I (IB, IA) are computed as follows: 
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where deg(IA) is the number of neighbors of vertex IA. 
3.2.4  Random walk with restart on the protein complexes network 
(RWPCN) 
We are now ready to present our proposed algorithm. Given a query phenotype pti, 
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the aim is to prioritize the candidate disease genes based on the known disease 
genes which are associated to    ’s similar phenotypic neighbors in the phenotype 
network. 
Initialization of seed genes and complexes 
Let N(pti) represents the k-NN phenotype neighbor set of the query phenotype pti 
where each ptj∈N(pti) is similar to pti. Let dis(pti) be the set of causative genes of 
the phenotype pti. We define the seed disease gene set with respect to pti as
( )
( )
j i
j
pt N pt
S dis pt

 . For a seed disease gene s∈ S , we assign to it a score
( )
( , ) ( , )
j
i j i
s dis pt
seed s pt L pt pt

  . Given a phenotype pti and the score for its seed 
gene set ( , )iseed s pt , the protein complex cA can be scored as follows: 
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(17) 
F(cA, pti) denotes initial score of the protein complex cA with respect to pti. 
The density of a graph G=(VG, EG), denoted as density (G), quantifies the richness 
of edges within G and it is defined as shown in equation (18): 
2*| |
( )
| | *(| | 1)
G
G G
E
density G
V V


      (18) 
Note that 0 ≤ density (G) ≤ 1. If density (G) = 1, then G is a complete graph, which 
means every pair of distinct vertices in VG is connected by an edge. As each protein 
complex can be viewed as a graph, we apply density(CA) to quantify the richness of 
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protein interactions within CA. 
Propagating the seeds’ influence to the complexes in the whole 
network 
The Random Walker algorithm [80] is applied to the protein complex network. First, 
the seed protein complexes are each assigned a score with respect to the query 
phenotype if they contain the genes in the seed disease gene set. Then all the protein 
complexes are scored in COM by propagation. We propose to do flow propagation 
for this. The disease influence flows initialized in seed complexes are distributed 
and pumped from seed complex vertices to their neighboring complexes in the 
network. These super vertices will then spread the influence flows received from 
previous iteration to their neighbors. 
Formally, let F0 be a vector of the initial probabilities of all the protein complexes in 
the protein complex network computed using equations (13-16). Fr-1 denotes the 
vector after r-1 iterations. The probability vector at step r, Fr, can be calculated by 
equation: 
2,)1( 01
'   rFFWF rr  ,     (19) 
where F1= F0, and W’ is the column normalized form, the transpose matrix of 
adjacency matrix W which is the transition matrix of the whole protein complex 
interaction network. We construct matrix W based on the three different links 
between protein complexes. Recall that the protein complex set COM consists of 
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both multi-protein complexes (CM) and individual complexes (CI). The matrix W is 
thus defined as: 
 
(20) 
where AC2C (n*n), AC2I (n*m), AI2C (m*n) and AI2I (m*m) are the adjacency sub-matrices. In 
particular, AC2C (n*n) represents the sub-network links between multiple-protein 
complexes, AC2I (n*m) represents the sub-network links from multi-protein complexes 
to individual complexes, AI2C (m*n) represents the sub-network links from individual 
complexes to multi-protein complexes, and AI2I (m*m) represents the sub-network 
links between individual protein complexes respectively, where n=|CM| and m=|CI| 
are the numbers of multi-protein complexes and individual complexes respectively. 
Note that in Equation (19), the parameter  ∈(0,1) provides a probabilistic 
weighting of spreading the prior information of the seed complex vertices to other 
protein complexes at every step.   is set as 0.8 in the experiments. At the end of 
the iterations, the prior information held by every vertex in protein complex 
network will reach a steady state. This is determined by the probability difference 
between Fr and Fr-1, represented as Dif=|Fr- Fr-1| (measured by L1 norm). When 
Dif=|Fr- Fr-1|<= 10
-10
, as suggested in Li et al. [22], we consider that a steady stage 
has been reached and stop the iterative process. Note that the function F is smooth 
over the whole protein complex-complex network, and each vertex complex is 
assigned a value to represent its association with the disease phenotype of interest. 
W = 
AC2C (n*n)  AC2I (n*m) 
AI2C (m*n)   AI2I (m*m) 
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Scoring disease gene based on associations of protein complexes to 
diseases 
Once the vector Fr reaches a steady state, we obtain the final scores of protein 
complexes with respect to query phenotype. Recall that the final objective of our 
algorithm is to prioritize the candidate disease genes amongst the genes in the GPPI. 
The final step is therefore to prioritize the candidate disease genes based on their 
associations with protein complexes. Given a candidate gene g, its association with 
query phenotype pti, denoted by S(g, pti), is computed as 
( , ) ( , )
A
i r A i
g c
S g pt F c pt

 
       
(21) 
where CA is the set of complexes containing the gene g. Especially, mutations on the 
genes shared by multiple protein complexes may lead to multiple similar 
phenotypes, so scores of these shared genes should be the accumulated score of 
protein complexes that contain them. 
The detail of the process of RWPCN is listed in Algorithm 3.1. 
Algorithm 3.1 Random Walk on Protein Complex Network (RWPCN) 
Input: 
W(A(m+n)×A(m+n)) //the adjacency matrix of the protein complex network 
F0 // the initial probability vector (A(m+n)×1) 
K: // the number of direct neighbors of one phenotype entry 
Output: RS:  
1. Calculate the density of protein complexes using Eq. 18 
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2. Initialize the probability vector F0 using Eq. 17 
3.            ; δ = 1; 
4. While δ ≥ 10-10 do 
5.                        ;// the random walk with restart algorithm 
6.    δ =                   
   
   ; 
7.         ; 
8. end while 
9. Ff = Fr; 
10. Calculate the score of candidate genes based on Ff; 
11.                           
12. Return RS; 
3.3 Experiment Results 
In this section, we will first describe the experimental data used. Then the 
experimental settings and evaluation metrics will be introduced. Finally, we present 
the experimental results compared to the state-of-the-art techniques. 
3.3.1  Experimental settings and evaluation metrics 
The objective is to uncover novel gene-phenotype relationships. In order to compare 
different techniques, we employ standard leave-one-out cross-validation in the 
experiments. Each known gene-phenotype association (g, p) is employed as one test 
case where the phenotype p is the query phenotype and the gene g is the test disease 
gene. In each round of cross-validation test, we will first intentionally remove the 
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association (g, p) from our data. Then the proposed algorithm is run to score the 
genes based on their associations with protein complexes with respect to the query 
phenotype p. If the test disease gene g is ranked as top 1, we will consider it as a 
successful prediction; otherwise it is a failed case. We use the number of overall 
successful predictions to evaluate the performance of different prediction methods. 
Depending on the genes involved in the ranking, we further categorize our 
evaluation metrics into the following two classes, namely, whole genome evaluation 
and ab initio evaluation [27]. Whole genome evaluation basically ranks all the genes 
to scan for disease genes, e.g. we can consider all HPRD genes which do not link to 
the query phenotype (exactly identical setting as RWRH [22]) and check how many 
known test disease genes are still ranked as top 1 in the cross-validation test. 
However, there are no causative genes for half of the OMIM phenotypes [81]. Ab 
initio prediction has been proposed to identify disease genes without any known 
disease genes for those query phenotypes [27]. For each phenotype entity, the 
gene-phenotype associations are removed from this phenotype p to all of its known 
causative genes
1
 and we can only use the other disease genes associated with p’s 
neighbor phenotypes as the seed disease gene set. If one of the known causative 
genes (assuming p is associated with multiple disease genes) related to the 
phenotype p is ranked top 1, we consider it a successful prediction. Noted in our 
experiments, the same experimental data and evaluation metrics have been 
                                                             
1
The difference between the whole genome evaluation and Ab initio evaluation lies in that for 
the whole genome evaluation, I only remove one phenotype gene association each time, but 
for Ab initio evaluation, multiple phenotype gene associations may be removed if the 
phenotype is associated with more than one causative genes.  
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consistently used to evaluate all the prediction techniques. 
3.3.2  Experimental Results 
In this section, we first compare our algorithm with two state-of-the-art techniques, 
namely, CIPHER-DN (CIPHER with the topological distance feature of Direct 
Neighbor) [27] and RWRH [22]. Next, the sensitivities of the parameters are tested 
in our proposed method. For discussion, we present a case study of predicting 
disease genes for two representative diseases i.e., Breast cancer and Diabetes. 
Finally, the scores for protein complexes are computed to discover if the protein 
complexes are disease related. 
Comparison with CIPHER-DN and RWRH 
We compare the performance of RWPCN algorithm with current computational 
techniques, namely, CIPHER-DN and RWRH, using the two evaluation metrics 
presented above, namely, whole genome evaluation and ab initio evaluation. Table 
3.1 shows the overall comparison results of different algorithms. In terms of whole 
genome evaluation (second column in Table 3.1), we observe that the proposed 
RWPCN is able to achieve the best result, successfully predicting 253 genes, which 
are 8 and 88 more genes predicted than RWRH and CIPHER-DN respectively. In 
terms of ab initio evaluation (third column in Table 3.1), the RWPCN is able to 
predict 226 disease genes successfully, which are 25 and 69 more than the RWRH 
and CIPHER-DN respectively. 
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Note that in the original CIPHER-DN paper [27], the authors have adopted a less 
strict evaluation metric for ab initio evaluation than mine. As long as the target gene 
was ranked among the top N (instead of the top 1), it was regarded as a successful 
prediction where N (N>=1) denoted the number of known disease genes for the 
query phenotype. Using this less stringent evaluation metric, our method predicts 
240 genes successfully while CIPHER-DN could only predict 157 genes in the ab 
initio evaluation. 
Table 3.1: Overall performance of RWRH, CIPHER-DN and RWPCN algorithm 
Algorithm  Whole genome evaluation  Ab initio evaluation 
RWPCN  253  226 
RWRH  245  201 
CIPHER-DN  165  157 
In the evaluations above, we have used the standard (but old) gene-phenotype 
association data which were also used in [27] [22] for comparison. To further 
validate the predicted associations, we collect a new version of gene-phenotype 
association data extracted from OMIM recently [82]. It contains 1614 
gene-phenotype associations, which includes 274 novel gene-phenotype 
associations where the disease genes were unknown in the previous version (other 
1340 associations are shared by both versions). Table 3.2 shows that using the new 
gene-phenotype association data, RWPCN successfully ranks the 273 (a sensitivity 
of 0.169) genes as top 1 in terms of whole genome evaluation, and 247 (a sensitivity 
of 0.153) in terms of ab initio evaluation, which are only slightly lower than the 
results of BIOMART in whole genome (a sensitivity of 0.177) and ab initio (a 
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sensitivity of 0.158) respectively, indicating our method is certainly capable of 
detecting the novel knowledge which are absent in the older reference data. 
We have constructed three levels of networks in our model. It is thus not 
strange that our method needs more computations. We may explore how to 
improve the efficiency of our algorithm in our future work, using better data 
structures and specific libraries for matrix operation, etc. 
Table 3.2: Overall performance of BIOMART06, 09 and 06+09 phenotype-gene 
Phenotype-gene data  Whole genome evaluation  Ab initio evaluation 
BIOMART06  253  226 
BIOMART09  273  247 
BIOMART06+09  285  253 
Effect of parameters   and k in RWPCN 
Recall that we have two parameters   and k in RWPCN algorithm. The flow 
parameter   is used in our RWPCN algorithm to control the proportion of 
information that flows back into the seed nodes/protein complexes at each iteration 
of the algorithm. A larger   represents that information flows are likely to return to 
the seed nodes, therefore those protein complexes near to seed nodes are more 
likely to be ranked forward. On the contrary, a smaller   represents that 
information flows are likely to flow out of the seed nodes, therefore those protein 
complexes near to seed nodes are more likely to be ranked backward. The second 
phenotype parameter k decides the number of related phenotypes with regard to the 
query phenotype. An unnecessarily large k will include many related phenotypes 
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which are not relevant while a smaller k will include smaller number of related 
phenotypes and may miss out some important relevant phenotypes as a result. 
We first investigate how the flow parameter   affects the performance of the 
algorithm. We run our algorithm using leave-one-out cross-validation with values of 
  ranging from 0.2 to 0.9 in steps of 0.1, while keeping the phenotype k fixed to 
10. The performance of the algorithms is measured using whole genome evaluation 
and Ab initio evaluation mentioned above. The results are shown in Figure 3.2. 
 
Figure 3.2: Effect of value   based on whole genome and ab initio evaluation 
With increasing values of  , we are able to obtain increased numbers of successful 
predictions for both whole genome evaluation and ab initio evaluation. This is 
expected since the seed nodes in protein complex network are more likely to hold 
the information flows, thus few flows will be distributed to the distant neighbors in 
the network. Biologically, this is reasonable since the protein complexes (and the 
corresponding proteins in the complexes) that directly interact with the disease 
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complexes/proteins are more likely to be disease/phenotype related. We observe that 
the performance of RWPCN with  >=0.4 are better than the existing CIPHER-DN 
and RWRH algorithms. In fact, we find that the optimal values of   can be found 
within a large range of 0.5<=  < =0.9. As such, selecting a suitable value for   for 
good performance is not a problem. 
To study the effect of the parameter k that decides the number of related phenotypes, 
we run RWPCN with k varying from 7 to 12 and  = 0.8, based on whole genome 
and ab initio evaluations. Results are shown in Figure 3.3. The performance of 
RWPCN algorithm is improved with increased value of k from 7 to 10, indicating 
that incorporating more related phenotypes is helpful for prioritizing target disease 
genes. However, if we further include more phenotypes (e.g. k>10) with low 
phenotypic similarities, noisy and un-meaningful phenotypes will be included [74] 
and eventually affects the performance of disease gene prediction. For example, the 
results in Figure 3.3 show that the performance with k in the range of [11, 12] has 
worsened. Nevertheless, the performance of RWPCN algorithm with k in the wide 
range [7, 12] is consistently better than that of RWRH, suggesting that RWPCN is 
insensitive to the specific values of k as far as comparison with RWRH is 
considered. 
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Figure 3.3: KNN phenotype network on whole genome and ab initio evaluation. 
Inferring novel causal genes for breast cancer and diabetes 
We also apply our method for uncovering novel candidate genes on specific 
complex genetic diseases. We have chosen Breast Cancer (MIM: 114480) and 
Diabetes Mellitus type 2 (MIM: 125853) for our case study here.  
We run the RWPCN algorithm (with k=10 and = 0.8) for Breast Cancer and 
Diabetes Mellitus type 2. Note that no gene-phenotype associations are removed 
since the aim is to predict the disease genes instead of cross-validation. We rank the 
resulting candidate genes over the whole genome and selected the top 20 ranked 
genes associated with target phenotypes (Breast Cancer and Diabetes Mellitus type 
2). The experimental results are listed in Tables 3.3 and 3.4 for Breast Cancer and 
Diabetes Mellitus type 2 respectively. 
Genes marked with * are known disease genes associated with target phenotype, 
genes marked with   are genes associated with target phenotype either extracted 
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from literature or from database, genes marked with ～ are un-related to target 
phenotype. 
Table 3.3: Breast cancer genes prediction 
Rank Score HGNC Gene symbol Mark 
1 3.61665 BRCA1  * 
2 2.64458 RBBP8    
3 1.04115 HDAC1   
4 1.02108 HDAC2   
5 1.00632 CTBP1   
6 0.983392 LMO4   
7 0.814445 RAD51  * 
8 0.812762 BRCA2  * 
9 0.807072 NBN  * 
10 0.806886 BRIP1  * 
11 0.801356 PIK3CA  * 
12 0.671104 ZNF350   
13 0.142519 SMAD3   
14 0.141945 ELAC2   
15 0.141729 RNASEL   
16 0.140748 PTEN   
17 0.0947266 TP53 ～  
18 0.0849672 SMAD4 ～  
19 0.0831955 EP300 ～  
20 0.0721527 CREBBP ～  
Table 3.3 shows six highly ranked genes that are also known to associate with the 
Breast Cancer. However, we are more interested in investigating whether the 
predicted novel susceptible genes are also associated with the disease phenotypes. 
We search for additional gene-phenotype associations from GENECARDS database 
[83] and also perform literature search from Pubmed on the other susceptible genes 
predicted by the algorithm to be associated with the disease phenotypes of breast 
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cancer. Eight additional genes are found, namely RBBP8, HDAC1, HDAC2, 
CTBP1, LMO4, ZNF350, SMAD3, ELAC2, RNASEL and PTEN that are also 
reported to be related to the Breast Cancer. For CtIP (also known as retinoblastoma 
binding protein 8, RBBP8, ranked at top 2), the expression of this gene has been 
shown to be a novel mechanism for tamoxifen resistance development in breast 
cancer [84]. HDAC1 and HDAC2 (ranked at top 3 and 4), among class I HDACs, 
are reported to regulate the changes in histone acetylation and are associated with 
HDAC inhibitors that are expected to reverse hypoacetylation levels observed even 
at the early stages of breast cancer progression [85]. CtBP1 (ranked at top 5) is 
confirmed to be associated with breast cancer and its activation has a potential 
impact in breast cancer development [86]. LMO4 (ranked at top 6) is a novel cell 
cycle regulator with a key role in mediator of ErbB2/HER2/HER2/Neu-induced 
breast cancer cell cycle progression [87]. Genetic variants and haplotype analyses of 
the ZNF350 (ranked at 12) gene suggest that it is associated with high-risk non 
BRCA1/2 French Canadian breast and ovarian cancer families [88]. Germ line 
mutation in RNASEL (ranked top 15) predicts increased risk of breast cancer [89]. 
SMAD3 (ranked at top 13) has critical roles in stimulation of breast cancer growth 
and metastasis [90]. Finally, Tsou HC et al. [91] reported three novel 
MMAC1/PTEN (ranked at 16) mutations in CS (Cowden syndrome) are associated 
with breast cancer.  All these show that our prediction method can discover novel 
disease genes for breast cancer beyond the original disease gene set. 
In the table list of candidate genes unmatched with breast cancer, TP53 is direct 
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neighbor of confirmed disease gene BRCA1, two suspicious disease genes, HDAC1 
and HDAC2. SMAD4 is directly linked to disease gene BRCA1, and share identical 
neighbor EP300 with confirmed disease gene NBN. CREBBP has protein 
interactions to confirmed disease genes BRCA1 and suspicious disease gene 
HDAC1. 
Table 3.4: Diabetes genes prediction 
Rank Score HGNC Gene symbol Mark 
1 1.34591 PIK3R1   
2 1.33691 IRS1  * 
3 1.33691 INSR  * 
4 1.33691 KHDRBS1   
5 0.821847 NEUROD1  * 
6 0.812877 IPF1  * 
7 0.810154 SLC2A4  * 
8 0.802705 MAPK8IP1  * 
9 0.802453 TCF2  * 
10 0.802404 PPP1R3A  * 
11 0.354724 TCF1 ～  
12 0.194629 CREBBP ～  
13 0.15557 EP300   
14 0.102423 PCAF ～  
15 0.0807789 PLN ～  
16 0.0806853 RPS6KA1 ～  
17 0.0652625 CUL3 ～  
18 0.0652625 SPOP ～  
19 0.0595811 POLR2A ～  
20 0.0471911 ABCC8   
Table 3.4 shows our prediction results for Diabetes Mellitus type two. Out of the top 
20 predicted disease genes, eight genes are known to associate with the phenotype. 
We find three additional genes PIK3R1, EP300 and ABCC8 to be related to the 
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disease phenotypes. PIK3R1 (ranked as top 1) has been tested for their influence on 
insulin action, showing significant associations with diabetes [92]. KHDRBS1 
(ranked at top 4, aliases SMA68) is reported that its RNA binding protein is a 
potential target to treat diabetes and obesity [93]. EP300 (ranked at top 13, aliases 
p300), as a transcriptional coactivator, can cause diabetes via regulating fibronectin 
expression via PARP and NF-kappaB activation [94]. For ABCC8, a rare mutation 
in ABCC8/SUR1 (ranked at top 20) has been reported to have an effect on K(ATP) 
channel activity and beta-cell glucose sensing, leading to diabetes in adulthood [95]. 
In the table list of candidate genes unmatched to diabetes mellitus type 2, TCF12 
and CREBBP have protein interactions to suspicious disease gene EP300. PLN and 
RPS6KA1 are directly interacted to confirmed disease gene PPP1R3A at molecular 
level. CUL3 and SPOP are involved in same protein complex. This complex and 
POLR2A share identical protein interaction neighbor with suspicious disease gene 
EP300. 
From Tables 3.3 and 3.4, we find our predicted disease genes indeed mapped 
significantly with disease genes that are either curated in existing database or 
reported in the literature. Though unmatched genes are not associated with any 
positive evidences in current databases or literatures, they are closely interacted 
with confirmed disease genes in protein-protein interaction network or involve in 
protein complexes containing confirmed disease genes. As such, they are good 
candidates for biologists and clinicians to do experiments for validation. 
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To investigate the significance of our top selected candidate genes, two disease gene 
prioritization approaches are applied to prioritize novel disease genes associated 
with breast cancer and diabetes mellitus type 2. One is random walk with restart 
(RWR) that was used in [25], who run the algorithm on PPI network without 
considering protein complex information. The other one is random selection, in 
which we randomly permutate all the genes and select five groups of top 20 
candidate genes for breast cancer and diabetes mellitus type 2 respectively. Same 
measurement has been proposed to five groups of 20 genes to evaluate the 
association to target phenotypes. We compare top 20 candidate genes selected by 
our method with genes that are predicted by RWR and random selection, and report 
the result in the table 3.5. The results show that our method is better than RWR and 
random selection on breast cancer and diabetes gene prioritization. 
Table 3.5: Comparison with random selected genes 
disease 
method 
breast cancer (114480) diabetes mellitus type 2 (125853) 
confirmed suspicious unmatched Confirmed suspicious unmatched 
RWPCN 6 10 4 8 4 8 
RWR 6 5 9 8 2 10 
Random 0 2.8 17.2 0 0.6 19.4 
 
Detecting disease-related protein complexes 
Recall that we have assigned scores to the protein complexes to indicate the degree 
of association of the protein complexes to the query disease phenotypes. Protein 
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complexes assigned high scores indicate strong associations to corresponding 
phenotypes. Based on the scores, we have ranked the protein complexes and studied 
the top two complexes here: sarcoglycan-sarcospan complex (SG-SPN) and 
Pex26-Pex6-Pex1 complex. For evaluation, a set of 248 disease protein complexes 
from Lage et al. [29] are used as our benchmark. 
 
Figure 3.4: SG-SPN overlaps with the disease complex No. 230. 
Figure 3.4 shows that the SG-SPN complex (surrounded by green line) contains five 
human proteins: Q16586, Q16585, Q92629, Q13326, Q14714, and it rank at top 1 
protein complex for phenotype OMIM: 608099 by RWPCN algorithm. We find that 
this SG-SPN complex has a large overlap (shared four proteins) with the disease 
complex No. 230 (surrounded by red dash line) in our benchmark set. We also find 
that the shared four proteins are linked to disease phenotypes (blue dash links), 
which have high phenotypic similarity among them. Note that gene Q14714 (SSPN) 
in SG-SPN complex is associated with phenotype Fukuyama Congenital Muscular 
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Dystrophy (FCMD) (MIM: 253800) [96] which is closely related to phenotype 
OMIM: 608099 in our phenotype network, indicating that SG-SPN complex could 
indeed be a valid disease complex. 
 
Figure 3.5: Pex26-Pex6-Pex1 overlaps with the disease complex No. 335. 
Similarly, Figure 3.5 shows the Pex26-Pex6-Pex1 complex (surrounded by green 
line) which covers a benchmark disease complex (surrounded by red dash line) that 
consists of proteins O43933 (PEX 1) and Q13608 (PEX 6). The Pex26-Pex6-Pex1 
complex is involved in peroxisome biogenesis disorders (PBDs), which includes 
the Zellweger syndrome spectrum (PBD-ZSD) and rhizomelic chondrodysplasia 
punctata type 1 (RCDP1). PBD-ZSD represents a continuum of disorders 
including infantile Refsum disease (MIM: 266510), neonatal adrenoleukodystrophy 
(MIM: 202370), and Zellweger syndrome (MIM: 214100). Note that the Q7Z412 
(PEX 26) protein in our predicted disease complex is also a known disease gene 
associated with all the three phenotypes, suggesting that the mutations of proteins in 
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the same CORUM protein complexes are likely to induce the same or similar 
phenotypes. It also shows that our highly ranked protein complexes are indeed 
disease related. 
Disease gene modules in PAGES database 
While RWPCN is significant for complementing the weaknesses of individual 
molecular interaction networks, it relies on the human protein complex interaction 
network. Therefore the spotty coverage of the protein complex data can affect the 
performance of prediction. To increase the coverage, we extract “disease gene 
modules” in the PAGED database [97]. 
We utilize PAGED disease gene modules in our RWPCN algorithm to uncover 
novel candidate genes on Breast Cancer (MIM: 114480) and Diabetes Mellitus type 
2 (MIM: 125853) for our case study here.  
We renew our protein complex network with additional PAGED disease modules 
and then run the RWPCN algorithm for Breast Cancer and Diabetes Mellitus type 2. 
Following experimental setting in Table 3.3 and 3.4, the top 20 ranked genes are 
selected to assess our algorithm performance. The experimental results are listed in 
Tables 3.6 and 3.7 for Breast Cancer and Diabetes Mellitus type 2 respectively. 
Genes marked with *,   and ～ are represented as confirmed disease genes, 
genes with literature support and un-related genes to target phenotype. 
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Table 3.6: Breast cancer genes prediction using PAGED dataset 
Rank HGNC Gene symbol Score Mark 
1 BRCA1 4.32062 * 
2 EP300 4.31291 ～  
3 CASP8 4.18623 * 
4 FANCC 3.54481   
5 FANCG 3.54481   
6 FANCF 3.54481   
7 FANCA 3.54481   
8 ERCC1 3.38491 ～  
9 ERCC4 3.38491   
10 ESR1 3.36958 * 
11 NCOA3 3.31292   
12 RBBP8 3.1943   
13 FADD 3.073   
14 CREBBP 3.05405 ～  
15 SMAD3 2.93813   
16 KAT2B 2.82028   
17 PARD3 2.54331 ～  
18 RPA1 2.54269   
19 RPA2 2.54269   
20 RPA3 2.54269 ～  
 
Table 3.6 shows three highly ranked genes that are also known to associate with the 
Breast Cancer. We search for additional gene-phenotype associations from 
GENECARDS database and also perform literature search from Pubmed on the 
other susceptible genes predicted by the algorithm to be associated with the disease 
phenotypes of breast cancer. 12 genes are associated with breast cancer in our 
literature research, which are better than predicted results on CORUM in Table 3.3. 
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Table 3.7: Diabetes genes prediction using PAGED dataset 
Rank HGNC Gene symbol Score Mark 
1 PIK3R1 1.75811   
2 IRS1 1.56845 * 
3 INSR 1.56845   
4 KHDRBS1 1.56845   
5 HNF1A 1.15679   
6 ADIPOQ 1   
7 ADIPOR2 0.9   
8 KCNJ11 0.895163 * 
9 ABCC8 0.882255 * 
10 ACP1 0.843614   
11 CYP3A4 0.833333   
12 FBXO38 0.833333 ～  
13 CCR5 0.831326   
14 ADRB2 0.829597   
15 CREB1 0.82954   
16 NEUROD1 0.824896   
17 SPINK1 0.819611   
18 CLU 0.819265 ～  
19 EXT2 0.817123   
20 AGT 0.816536   
Table 3.7 shows our prediction results for Diabetes Mellitus type 2 under PAGED 
disease modules and there are three known disease genes and 15 suspicious genes in 
top20 ranking list. Although merely three known disease genes have high rank, we 
are more interested in novel disease gene prediction. In the table, 15 genes are 
associated with diabetes mellitus type 2, which are supported by GENECARDS 
database as well as PubMed literatures. The significant prediction result may be 
attributed to confirmed gene modules from PAGED, which collected gene/protein 
modules associated with particular diseases. Therefore, genes involved in PAGED 
gene modules are more likely to be prioritized in renewed protein complex network. 
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Algorithm convergence rate and computational complexity 
It is known that the network matrix, defined as M, has     eigenvalues   ,   , …, 
     such that                   . The eigengap of M is defined as 
         , which provides a bound of the convergence time. A larger eigengap 
means shorter convergence time [98]. Therefore, the computational complexity of 
random walk is related to network structure. The proposed protein complex network 
(PCN) is induced from the human PPI network without increasing nodes and edges, 
therefore the complexity of random walk on PCN equals to that on PPI network. 
Compared to RWRH [22] and the work [25], proposed RWPCN has comparative 
efficiency in computational complexity and convergence rate. 
Discussion on RWPCN advantages 
Many specific examples show that genes causing similar phenotype tend to be 
linked at biological levels as components of a multi-protein complex. Protein 
complexes, as molecular machines that integrate multiple gene products to perform 
biological functions, are direct manifestations of biological modules. In the other 
side, protein complexes sharing common proteins, the mutations of genes in one 
protein complex could lead to same or similar phenotypes of the other protein 
complex. Therefore, a novel protein complex network is constructed where nodes 
are individual complexes and the interactions between two complexes are measured 
by connection strengths. The proposed protein complex network can be a useful 
basis for interrogating the networks of phenome and interactome to elucidate 
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gene-phenotype associations of diseases. 
3.4  Summary 
While great progress has been made in genomics and proteomics, discovering the 
associations between genes and phenotypes have remained as challenges. In this 
chapter, we construct a novel human protein complex network by integrating HPRD 
protein interaction network and CORUM protein complexes. The result shows that 
a genome-wide disease gene prioritization for multi-factorial diseases can be 
obtained using such a human protein complex network. Using our method, the top 
ranking candidate disease genes that are found to be closely associated with protein 
complex can potentially be used to guide the prediction of disease-related protein 
complexes. 
It should be acknowledged that the proposed RWPCN algorithm can be improved 
further. As RWPCN relies on the human protein complex interaction network, the 
coverage of the protein complex data can affect the performance of prediction. 
Since the current protein complex data is by no means complete, predicted human 
protein complexes with high quality could be taken into consideration. Combining 
the predicted and experimentally validated complex data into the prioritization 
process (e.g. using the method reviewed in [99]), can increase the power of 
prediction as long as the quality of the complex data is ensured. RWPCN also 
depends on the quality (i.e. reliability) of the PPI data which is considered in the 
current model. It is well-known that PPI data generated with high-throughput 
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methods can be of inferior quality. One possible improvement is to assign weights 
to protein-protein interactions using diverse biological evidences (e.g. protein 
sequences, domain, motif, topological properties of PPI network [100], protein 
localization, molecular function, biological process and gene expression profiles, 
etc) to improve the reliability of the PPI data that we use for disease gene 
prioritization. We are currently exploring these and other approaches to further 
improve our RWPCN algorithm for discovering gene-phenotype associations. 
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Chapter 4.  
Positive Unlabeled Learning for disease 
gene identification 
Machine learning methods can be applied to discover new disease genes based on 
the known ones. Existing machine learning methods typically use the known 
disease genes as the positive training set P and the unknown genes as the negative 
training set N (non-disease gene set does not exist) to build classifiers to identify 
new disease genes from the unknown genes. However, such kind of classifiers is 
actually built from a noisy negative set N as there can be unknown disease genes 
in N itself. As a result, the classifiers do not perform as well as they could be. 
Instead of treating the unknown genes as negative examples in N, we treat them as 
an unlabeled set U. We design a novel Positive-Unlabeled (PU) learning algorithm 
PUDI (PU learning for Disease gene Identification) to build a classifier 
using P and U. We first partition U into four sets, namely, reliable negative set RN, 
likely positive set LP, likely negative set LN, and weak negative set WN. The 
Weighted Support Vector Machines are then used to build a multi-level classifier 
based on the four training sets and positive training set P to identify disease genes. 
Our experimental results demonstrate that our proposed PUDI algorithm 
outperformed the existing methods significantly. 
The proposed PUDI algorithm is able to identify disease genes more accurately by 
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treating the unknown data more appropriately as unlabeled set U instead of negative 
set N. Given that many machine learning problems in biomedical research do 
involve positive and unlabeled data instead of negative data, it is possible that the 
machine learning methods for these problems can be further improved by adopting 
PU learning methods, as we have done here for disease gene identification. 
4.1 Introduction 
Recent studies have revealed that genes associated with similar disorders have been 
shown to demonstrate higher probabilities of similar gene expression profiling [47], 
high functional similarities [26] and physical interactions between their gene 
products [1] [31]. As such, those unknown genes that share similar gene expression 
profiles with the confirmed disease genes, have high functional similarities with 
disease genes and interact with disease gene products are likely to be disease genes 
as well.  Xu et al. [34] employed the K-nearest neighbor (KNN) classifier to 
predict disease genes based on the topological features in PPI networks, such as 
proteins’ degree, the percentage of disease genes in proteins’ neighborhood, etc. 
Smalter et al. [35] applied support vector machines (SVMs) classifier using PPI 
topological features, sequence-derived features, evolutionary age features, 
etc. Radivojac et al. [101] first built three individual SVM classifiers using three 
types of features, i.e. PPI network, protein sequence and protein functional 
information, respectively. It then built a final classifier by combining the predictions 
from three individual classifiers for candidate gene prediction. 
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The above works employed machine learning methods to build a binary classifier 
by using the confirmed disease genes as positive training set P and some unknown 
genes as negative training set N. However, since the negative set N will contain 
unconfirmed disease genes (false negatives), which confuses the machine learning 
techniques for building accurate classifiers. As such, the classifiers built based on 
the positive set P and noisy negative set N do not perform as well as they could in 
identifying new disease genes. 
To address this issue, we design a novel positive-unlabeled (PU) learning algorithm 
PUDI (PU learning for disease gene identification) to build a more accurate 
classifier based on P and U [37] [38] [39]. First, we use a comprehensive 
combination of biological process, molecular function, cellular component, protein 
domain and PPI data to represent the genes into feature vectors. We design a novel 
feature selection method to reduce the dimensionality of the feature vectors. Then, 
we partition U into four label sets, namely, reliable negative set, likely positive set, 
likely negative set, and weak negative set, based on their likelihoods being 
positive/negative class. Finally, we build multi-level weighted SVMs using these 
four sets together with positive set P for identifying disease genes. 
To the best of our knowledge, PUDI is the first to design a novel multi-level PU 
learning algorithm for building a classifier for disease gene identification. We have 
compared PUDI with three state-of-the-art techniques, namely, Smalter’s method 
[35], Xu’s method [34] and ProDiGe [36] method. Our experimental results showed 
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that PUDI outperforms the existing methods significantly for predicting 
general disease genes and for identifying disease genes in eight specific disease 
classes, such as cardiovascular diseases, endocrine diseases, psychiatric diseases, 
metabolic diseases and cancer, etc. 
4.2 Method 
In section 4.2.1, we introduce a method to characterize genes into feature vectors 
using different biological features. In section 4.2.2, we propose a novel feature 
selection method to choose distinguishing features for better classification. Finally, 
we describe our proposed positive unlabeled learning procedure in section 4.2.3. 
The system schema and data flow of PUDI are shown in Figures 4.1 and 4.2 
respectively. 
 
Figure 4.1: The Schema of PUDI algorithm 
 73 
 
 
Figure 4.2: The data follow of PUDI algorithm 
4.2.1  Gene characterization 
Our approach is to characterize genes (or corresponding gene products) using a 
comprehensive range of biological information. The information includes protein 
domains (D), molecular functions (MF), biological processes (BP), cellular 
components (CC), as well as the genes’ corresponding topological properties in the 
protein interaction networks (PPI). In other words, each gene gi is represented as a 
vector Vgi which consists of a domain component Dgi, a molecular function 
component MFgi, a biological process component BPgi, a cellular component 
component CCgi, and a protein interaction component PPIgi, i.e. Vgi =(Dgi, MFgi, 
BPgi, CCgi, PPIgi). We describe each of these components in details below. 
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Protein domains are evolutionarily conserved modules of amino acid sub-sequence 
postulated that as nature’s functional “building blocks” for constructing the vast 
array of different proteins. Protein domains are thus regarded as essential units for 
such biological functions as the participation in transcriptional activities and other 
intermolecular interactions. Databases, such as the Protein families (Pfam) database 
and others, have been compiled to comprise comprehensive information about 
domains (http://www.sanger.ac.uk/Software/Pfam) [102]. In this study, we only 
used Pfam-A, a collection of manually curated and functionally assigned domains, 
instead of Pfam-B, which is computationally derived collection of domains (and 
hence less accurate), to ensure accuracy in our predictions. The domain component 
Dgi of the given gene gi is represented as Dgi = (di1, di2, …, di|Pfam-A|) where dij (1≤ j 
≤ |Pfam-A|) is equal to 1 if gi’s gene product contains the corresponding domain in 
Pfam-A; 0 otherwise. 
For the molecular function component MFgi, biological process component BPgi, 
and cellular component component CCgi, we use the Gene Ontology (GO, 
http://www.geneontology.org/) database, which provides a common vocabulary that 
can be used to describe the biological processes (BP), molecular functions (MF) and 
cellular components (CC) for the genes [50]. 
Let SMF={MF1, MF2, …, MF|SMF |}, SBP={BP1, BP2, …, BP|SBP|)} and SCC ={CC1, 
CC2, …, CC|SCC |} represent the set of MF, BP and CC in GO respectively. Then 
MFgi = (mfi1, mfi2, …, mfi|SMF |), BPgi = (bpi1, bpi2, …,  bpi|SBP|), CCgi= (cci1, cci2, …, 
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cci|SCC |). Let us take MFgi as an example (similar for BPgi , CCgi) to show how to 
compute each element mfij (1≤ j ≤ |SMF|). Note that each gi can be annotated by 
many GO terms at different levels in GO’s DAG structure (Direct Acyclic Graphs). 
For example, the gene ADH4 is annotated by molecular function term set {0004022, 
004024, 0004174, 0046872, 0008270, 0004023} in the GO database. Assume that gi 
has the following molecular functions FUNgi ={fun1, fun2, …, funk}, mfij can be 
computed as follows:  
                
                                   (22) 
where sim_go(funl, MFj) is the GO term similarity between two functions funl and 
MFj. Since the GO terms of BP, MF and CC are organized into DAG structure, we 
use the computational method proposed in [103] to compute the similarity between 
two GO terms A and B. Let the GO term A be represented as             , 
where    includes term A and all of its ancestor GO terms in the DAG graph, and 
   is the set of edges (semantic relations) connecting the GO terms in   . For a 
term t in             , its S-value related to term A,      , is defined as: 
  
                                                                                 
                 
                            
    (23) 
where    is the weight for edge      linking term   with its child term  
 . 
The weights    for two types of edges “is a” and “part of” are assigned as 0.8 
and 0.6 respectively, as recommend in [103]. 
Given              and              for GO terms A and B respectively, 
 76 
 
the similarity between A and B, sim     , is defined as: 
                                                  (24) 
where                 .  
For the protein interaction component PPIgi, we exploit a protein interaction 
network GPPI = (VPPI EPPI) where VPPI represents the set of the interacting proteins 
and EPPI denotes all the detected pairwise interactions between proteins in VPPI. We 
use four topological features from GPPI [34] for gene gi as PPIgi = (degreei, 1Ni, 2Ni, 
Clusteri). degreei=|Ni|=|{u|u VPPI, (gi, u) ⊆ EPPI}| where Ni  is the set of gi’s direct 
neighbors in GPPI  and degree of gi is the cardinality of Ni. 1Ni represents the 
proportion of disease genes in Ni which is defined as 1Ni =|{u|u Ni∩P}|/degreei. 
Similarly, 2Ni represents the proportion of disease genes in gi’s larger neighborhood 
(with radius 2, i.e. including gi’s direct neighbors and indirect neighbors). Clusteri is 
the clustering coefficient which measures the degree to which gi’s direct neighbors 
in GPPI tend to cluster together [104]. 
4.2.2  Feature Selection 
We have represented each gene gi using a comprehensive list of biological features. 
In this section, we propose a novel feature selection method to choose subsets of 
features that are useful for distinguishing disease genes from non-disease genes. 
For each feature f in BP, MF, CC and D, we compute its affinity frequency in the 
positive set P af(f, P) and the unlabeled set U af(f, U): 
 77 
 
                                             (25) 
                                             (26) 
where            is the association score between a gene gi in P (or U) and the 
feature f. If (f  BP MF CC), then 
                                                         (27) 
In other words, we compute the association score using the maximal GO term 
similarity between feature f and each of the gi’s GO terms. In the case of f ∈D, 
             if f ∈D(gi) (or feature f belongs to gene gi’s domain set); 0 
otherwise. We evaluate each feature f by its discrimination ability score: 
                             
   
      
 
   
      
     (28) 
Our objective is to choose those distinguishing features that either frequently 
occurred in the disease gene set P but seldom occurred in unlabeled gene set U 
(assuming large portion of unknown genes are still negatives), or frequently 
occurred in U but seldom occurred in P. In this way, we choose the features which 
can help us to distinguish disease genes from non-disease genes. Let us see how 
equation 28 helps us do that. We can see from the equation that given a feature f, if 
its affinity frequency in P af(f, P) is large while its frequency in U af (f, U) is small, 
or the frequency in U af(f, U) is large while the frequency in P af (f, P) is small, 
then the value of da(f) will be large since both factors                 
             and                 are large. When af(f, P) and af(f, U) are 
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both large, then the value of                             will be small, 
hence, da(f) will be relatively small. Similarly, when af(f, P) and af(f, U) are both 
small, the value of                 will be small, and da(f) will also be 
relatively small.  
With a reduced feature set formed by equation 28, we are able to speed up the 
computation for building a classification model, as well as avoid potential model 
over-fitting. Table 4.1 and 4.2 list some examples of highly-ranked GO and domain 
features, indicating the features selected are indeed associated with various diseases. 
Table 4.1: The distinguishing features for BP, MF and CC 
GO term GO Definition 
Disease Gene 
Number 
GO:0007165 BP signal transduction; signaling cascade 389 
GO:0050896 BP Response to stimulus; Physiological response to 
stimulus 
172 
GO:0007166 BP Cell surface receptor signaling pathway; Cell 
surface receptor linked signaling pathway; 
89 
GO:0035556 BP Intracellular signal transduction; Intracellular 
signaling cascade 
64 
GO:0000166 MF Nucleotide binding 538 
GO:0008134 MF Transcription factor binding 101 
GO:0019899 MF Enzyme binding 89 
GO:0016020 CC Membrane 782 
GO:0005634 CC Nucleus; cell nucleus 1146 
 
Table 4.2: The distinguishing features for domain D 
Domain Disease name Disease 
gene 
 
 
 
 
HYPERTROPHIC NEUROPATHY OF DEJERINE-SOTTAS: 
145900; 
NEUROPATHY,CONGENITAL HYPOMYELINATING: 605253; 
CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, 
EGR2 
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PF00096 
TYPE 1D; CMT1D: 607678 
NEUTROPENIA, NONIMMUNE CHRONIC IDIOPATHIC, OF 
ADULTS: 607847 
GFI1 
PALLISTER-HALL SYNDROME; PHS:146510; 
POLYDACTYLY, POSTAXIAL, TYPE A1:174200; 
POLYDACTYLY, PREAXIAL IV:174700; 
GREIG CEPHALOPOLYSYNDACTYLY SYNDROME; GCPS: 
175700; 
HYPOTHALAMIC HAMARTOMAS CONGENITAL 
HYPOTHALAMIC HAMARTOMA SYNDROME, INCLUDED; 
CHHS, INCLUDED: 241800  
GLI3 
GASTRIC CANCER:137215;PROSTATE CANCER:176807 KLF6 
SALIVARY GLAND ADENOMA, PLEOMORPHIC": 181030 PLAG1 
DIABETES MELLITUS, TRANSIENT NEONATAL, 1: 601410 PLAGL1 
TOWNES-BROCKS SYNDROME; TBS:107480  SALL1 
IVIC SYNDROME:147750; 
DUANE-RADIAL RAY SYNDROME; DRRS:607323 
SALL4 
PIEBALD TRAIT; PBT:172800; 
WAARDENBURG SYNDROME, TYPE IID:608890  
SNAI2 
ASTHMA, SUSCEPTIBILITY TO:600807 
OBESITY LEANNESS, INCLUDED:601665 
ADRB2 
OBESITY LEANNESS, INCLUDED:601665 ADRB3 
HYPERTENSION, ESSENTIAL:145500 
RENAL TUBULAR DYSGENESIS;  RTD:267430  
AGTR1 
 
 
 
 
 
 
 
 
PF00076 
Neuroepithelioma:612219  EWSR1 
AMYOTROPHIC LATERAL SCLEROSIS 6:608030 FUS 
DIABETES MELLITUS, NONINSULIN-DEPENDENT; 
NIDDM:125853  
IGF2BP2 
OCULOPHARYNGEAL MUSCULAR DYSTROPHY; 
OPMD:164300  
PABPN1 
OBESITY LEANNESS, INCLUDED:601665  PPARGC1B 
OSLER-RENDU-WEBER SYNDROME 2; ORW2:600376 ACVRL1 
BREAST CANCER:114480 
COLORECTAL CANCER; CRC:114500 :167000  
PROTEUS SYNDROME:176920 
SCHIZOPHRENIA; SCZD:181500 
AKT1 
DIABETES MELLITUS, NONINSULIN-DEPENDENT; 
NIDDM:125853 
HYPOGLYCEMIA, NEONATAL, SIMULATING 
FOETOPATHIA DIABETICA:240900 
AKT2 
"PERSISTENT MULLERIAN DUCT SYNDROME, TYPES I 
AND II; PMDS":261550  
AMHR2 
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4.2.3  PU learning to identify the disease genes from U 
With the above feature representation and feature selection methods, we are now 
ready to build a classifier using the given confirmed disease gene set P and 
unlabeled gene set U. We call our proposed algorithm PUDI -- PU learning for 
Disease gene Identification. Given that we do not have any negative genes, the first 
step is to extract a set of reliable negative genes RN from U by computing the 
similarities of the unlabeled genes in U with the positive genes in P, based on the 
idea that those genes in U that are very dissimilar to the genes in P are likely to be 
reliable negatives [37]. 
The detailed algorithm is given in Algorithm 4.1. We initialize the reliable negative 
set RN as an empty set, and represent each gene gi in P and U as a vector Vgi using 
the feature representation method discussed in Section 4.2.1 and the feature 
selection method presented in Section 4.2.2. We build a “positive representative 
vector” (pr) by summing up the genes in P and normalizing it (Line 3). Lines 4-6 
compute the average distance of each gene gi in U from pr using the Euclidean 
distance, dist(pr, Vgi) [105]. For each gene gi in U, if its Euclidean distance dist(pr, 
Vgi) > Ave_dist, we regard it as a reliable negative example and store it in RN (lines 
7-9); since it is very far away from the positive examples, it is thus safe for us to 
treat it as a negative example. 
Algorithm 4.1 Selection of Reliable Negative samples RN from Unlabeled set U 
Input:  Set P and set U // training positive data and negative data vectors 
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Output:  RN: // output Reliable Negative 
1. RN = ; 
2. Represent each gene gi in P and U as a vector Vgi; 
3.        
   
       ;  
4. Ave_dist = 0; 
5. For each gi  U  do 
6.    Ave_dist+=dist(pr, Vgi)/|U|; 
7. For each gi  U  do 
8.    If (dist(pr, Vgi) > Ave_dist) 
9.      RN  = RN  {gi} 
At this point, we have a positive set P, a reliable negative set RN and a refined 
unlabeled set U-RN, so we can build a classifier using P and RN with any 
supervised learning method. However, the reliable negatives in RN may still be far 
away from the desired boundary between the actual positive and negative data. To 
build a robust classifier, an important next step in our PUDI algorithm is to further 
extract the likely positive examples LP and the likely negative examples LN from 
genes in the U-RN which are near the positive and negative classification boundary. 
To do so, we construct a gene similarity network                 , in which a 
vertex v in vertex set VSIM represents a gene in P U and an edge (gi, gj) in edge set 
     represents a connection between two distinct genes gi and gj. To construct 
    , we define the pairwise similarity matrix      etween any two genes gi and gj 
as follows: 
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   (29) 
A high value in     indicates that the two genes gi and gj share the similar 
biological evidence and thus likely belong to same category (disease or 
non-disease). For each gene         , we connect it with another gene if their 
similarities are among top Q most similar ones to gene   . This is to ensure that we 
keep only those robust connections in the network. With the resulting gene 
similarity network                 , we can then perform a random walk with 
restart algorithm to detect the likely positives and likely negatives, as follows: 
Step 1. Initialize the prior probabilities of positives and reliable negatives. Let    
and    denote the prior probability vector of the positives and reliable negatives, 
respectively. In    the prior probabilities of positive examples in P are assigned an 
equal probability +1 (with the sum of the probabilities equal to |P|). In   , the prior 
probabilities of the reliable negative examples in RN are assigned as -|P|/|RN| (so 
the sum of the probabilities equals to -|P|). This guarantees fair allocation of prior 
probabilities from the two sets of labeled data. We represent the overall prior 
probability vector for the training data as              
 , where        . 
The prior probabilities in    are assigned 0 and we will decide their posterior 
probabilities in step 2. 
Step 2. Propagate the label information influence from G0 to the genes of U-RN in 
the network. After initialing the prior probabilities for positive examples and 
reliable negative examples as above, we score all the remaining unlabeled genes in 
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the network by propagation. We propose to do flow propagation for this and adopt 
the Random Network algorithm [80] to our network     . The prior influence 
flows of labeled genes are distributed to their neighbors, which continue to spread 
the influence flows to other nodes iteratively. Formally, let    be the initial 
probability vector,   , the probability vector at step  , can be calculated as follows: 
                                (30) 
where       and      
     . Here D is the diagonal matrix with     
     . The parameter   provides a probabilistic weighting of the prior 
information returning back to initial genes at every step. In this work, we set 
parameter   to 0.8, as recommend in [22]. At the end of the iterations, the prior 
information held by every vertex/gene in the network will reach a steady state as 
proven by [80]. This is determined by the probability difference between    and 
    , represented as               (measured by L1 norm). When 
          [25] we consider that a steady stage has been reached and terminated 
the iterative process. 
Step 3. Label the likely positives and likely negatives. According to the posterior 
probabilities of   , we further partition the remaining unlabeled data U-RN data 
set into three parts: likely positives (LP), likely negative (LN) and weak negative 
(WN) using the following criteria: 
                   
                      
                      
                             
    (31) 
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We can now build a classifier using the given positive set P, and four extracted sets 
from U, namely, the reliable negative set RN, the likely positive set LP, the likely 
negative set LN, and the weak negative set WN. To take into account of the 
inherently different levels of trustworthiness of labels in P, RN, LP, LN and WN, we 
use a multi-level examples learning technique, Weighted Support Vector Machines 
[106] [107], to build a classifier. The objective function of Weighted Support Vector 
Machine can be defined as [108]:  
          
 
 
       
          
            
          (32) 
               
    
    
   
      
    
 
Subject to:                
                             
where    is a slack variable which allows the misclassification of some training 
examples, and   
 ,    
  ,    
 ,    
   and   
    represent the penalty factors for SVM to 
penalize the wrongly classified examples in P, RN, LP, LN and WN respectively. In 
particular,   
 >   
   since we are more confident with positive set P than the likely 
positive set LP. Correspondingly, we give a larger penalty if examples from P are 
classified as negative class than if examples from LP are classified as negative class. 
Similarly, condition   
 >   
   >   
    holds since we are more confident with RN 
than LN, and we are also more confident with LN than WN. We used ten-fold cross 
validation to decide the values for these penalty factors. 
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4.3 Result 
In this section, we present our experimental results on the comparisons of our 
proposed PUDI method with state-of-the-art techniques on general disease genes 
prediction, feature selection, parameter sensitivity analysis, specific disease gene 
prediction, and novel disease gene prediction. 
4.3.1  Experimental data, settings and evaluation metrics 
Experimental data. We downloaded the latest versions of disease gene data from 
GENECARD [109] and OMIM [81]. GENECARD and OMIM were then combined 
into our disease gene benchmark. There are 5405 known disease genes spanning 
2751 disease phenotypes after combining GENECARD data together with OMIM. 
Gene Ontology, consisting of three sub-ontology MF, BP and CC are downloaded 
from GO (http://www.geneontology.org/). Protein domains were obtained from 
http://www.sanger.ac.uk/Software/Pfam [102]. Human PPI data were downloaded 
from the HPRD [110] and OPHID [111]. The combined PPI dataset contained 
143939 PPIs involving a total of 13035 human proteins. 
Experimental settings. We chose the known disease genes with at least two-thirds 
non-zero features as our positive training set P. Here, |P|=3849 since not all the 
genes possess the MF, BP, CC, D and PPI features in the current data sources. We 
used ~16k genes from Ensembl [112] as the unknown gene set from which we 
randomly select the actual unlabeled set so that we have a balanced  |P| = |U|, 
following the setting in [33] [34] [35]. 
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We then performed feature selection and selected the top N scored features (the 
default value of N is 1000) for each of the four feature groups, i.e. BP, MF, CC, and 
D respectively. We executed ten-fold cross validation experiments to evaluate the 
performance of all the techniques on predicting general disease genes, and 
three-fold cross validation on predicting disease genes for specific disease groups.  
The average results are reported in Section 4.3.2.  
Evaluation metrics. We use the F-measure [113] to evaluate the performance of 
our classification systems. The F-measure is the harmonic mean of precision (p) and 
recall (r), and it is defined as F = 2 * p* r/(p+r). The F-measure reflects an average 
effect of both precision and recall. When either of them (p or r) is small, the value 
will be small. Only when both of them are large, the F-measure will be large. This is 
suitable since having either too small a precision or too small a recall for disease 
gene prediction is unacceptable and would be reflected by a low F-measure. 
4.3.2  Experimental Result 
Firstly, we compared our proposed PUDI algorithm with three state-of-the-art 
techniques, namely, Smalter’s method, Xu’s method and ProDiGe method for 
predicting general disease genes, i.e. automatically classify an unknown gene into a 
disease gene or a non-disease gene. We employed 10-fold cross validation and all 
the four methods above use the same groups of training and test set for fair 
evaluation. As mentioned earlier, both Smalter’s method and Xu’s method directly 
treat U as negative set. ProDiGe uses its bagging method to choose random subsets 
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RS from U and aggregate all the individual classifiers built using P and different RS. 
Our PUDI method partitions U into 4 label sets and then builds a multi-level 
Weighted SVM classifier that takes the confidence levels of these label sets into 
consideration. 
Table 4.3 shows that our proposed PUDI method is able to achieve 76.5% 
F-measure which is 14.2%, 15.1% and 2.0% better than Smalter’s method, Xu’s 
method (KNN with K=5) and ProDiGe method respectively. Particularly, compared 
with ProDiGe, our PUDI method achieves similar precision but 5.1% higher recall, 
indicating that our multi-level PUDI method can better handle the unlabeled data U 
for identifying the hidden disease genes in the test set. For Xu’s method, we 
increased its K value from 1 to 21, but its F-measure only changes slightly, ranging 
from 61.2-61.5. The experimental results in Table 4.3 confirm the benefits of 
appropriately processing the unknown gene set U. 
Table 4.3: Overall comparison among different techniques 
Techniques Precision (p) Recall (r) F-measure (F) 
PUDI 72.3% 81.0% 76.5% 
ProDiGe 72.4% 75.9% 74.5% 
Smalter’s method 62.9% 61.5% 62.2% 
Xu method (1) 65.0% 55.6% 59.9% 
Xu method (5) 66.3% 57.1% 61.3% 
Recall that we chose those disease genes with at least two-thirds non-zero features 
since they can provide sufficient informative information for classifiers building. To 
further evaluate the generalization ability of PUDI, we constructed 10 new test sets 
which consist of all the 121 poorly annotated disease genes and 10 groups of 
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randomly selected 121 unlabeled genes (both with less than two-thirds non-zero 
features). Interestingly, we observed that PUDI, in average, achieves 86.5% 
F-measure, indicating that PUDI classifier is robust enough to accurately identify 
those poorly annotated disease genes by automatically choosing  those highly 
distinguishing biological features. 
Table 4.4: Results of individual feature and combinations of features 
Category Precision (p) Recall (r) F-measure (F) 
BP 63.4% 81.3% 71.3% 
MF 50.3% 99.6% 68.6% 
CC 54.5% 93.5% 67.8% 
D 56.2% 86.5% 68.1% 
PPI 55.1% 88.2% 67.8% 
ALL-BP 65.3% 83.3% 73.2% 
ALL-MF 66.0% 84.7% 74.2% 
ALL-CC 67.4% 85.7% 75.4% 
ALL-D 62.3% 86.9% 72.6% 
ALL-PPI 67.9% 86.7% 76.1% 
Secondly, we conducted an experiment to investigate the effectiveness of the 
individual feature category and their combinations, as shown in Table 4.4 (Rows 
2-6 and 7-11 respectively). Among the five individual categories, using only the BP 
ontology achieves the highest F-measure (71.3%), higher than the other feature 
categories where they have higher recalls but much lower precisions. Further, we 
filtered out one category from the combined feature set each time. The results in 
Rows 7-11 showed that using a combined feature set without PPI category can gain 
better performance than those of other four kinds of combined feature groups. This 
is probably because we only have 4 PPI features, so removing them will only affect 
the classification performance slightly. Note the performance of using a combined 
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feature set without protein domains leads to the worst performance, indicating 
protein domains, as proteins’ evolutionarily conserved modules, are useful for 
identifying disease genes. The performance of using all the features (Table 4.3) is 
still the best, confirming that integrating all the available biological resources is 
very valuable for disease gene prediction task. 
Thirdly, we perform a sensitivity study for all the three parameters used in the 
algorithm, i.e. parameter N (used in our feature selection method to control the 
number of features from MF, BP, CC and D), parameter Q (decides the number of 
neighbors used in our gene similarity network) and parameter   (used in Random 
Network to decide how much the influence flows returning back to initial nodes). 
Recall that we have one parameter N in our feature selection method to control the 
number of features from MF, BP, CC and D. To study the effect of parameter N on 
the performance of our algorithm, we run our method with N from 500 to 2000 with 
step 500. The results are shown in Table 4.5. The performance is improved with 
increasing value of N from 500 to 1000, indicating that incorporating more features 
is helpful for classifying target disease genes. However, if we further include more 
features with low feature discrimination scores (say N=2000), noisy features will be 
included and eventually affect the performance of disease gene classification. 
Table 4.5: Effect of parameter N (in feature selection) to classification performance 
# Parameter N Precision (p) Recall(r) F-measure (F) 
500 70.8% 82.5% 76.2% 
1000 72.4% 81.0% 76.5% 
1500 70.2% 81.7% 76.2% 
2000 69.9% 82.0% 75.5% 
 90 
 
To study the effect of the parameter Q, we run our algorithm with Q from 3 to 9 
while fixing N = 1000. Results are shown in Table 4.6. The F-measure is slightly 
decreased with the value of Q from 5 to 9, indicating that incorporating more edges 
with relatively low similarities may introduce the noisy connections and thus affect 
the performance of disease gene identification. Nevertheless, the performance with 
parameter Q from 3 to 9 without very slight difference suggests that our algorithm 
is robust to the noisy gene connections and insensitive to the specific value of Q.  
Table 4.6: Effect of parameter Q (in constructing gene similarity network) to 
classification performance 
Parameter Q Precision (p) Recall(r) F-measure (F) 
3 71.9% 81.3% 76.3% 
4 72.2% 81.0% 76.3% 
5 72.4% 81.0% 76.5% 
6 72.5% 80.7% 76.4% 
7 72.0% 80.8% 76.2% 
8 72.3% 80.3% 76.1% 
9 72.6% 80.1% 76.2% 
Parameter   in random walk algorithm is used to control how much the influence 
flows returning back to initial nodes (Genes in P and RN) at each iteration of the 
algorithm. In addition, it is also used to be to judge unlabeled genes assigned to 
likely positive LP or likely negative LN. With a large   in random walk algorithm, 
the flows are likely to return to the seed nodes. Therefore the nodes near to seeds 
are likely to gain higher scores to be assigned to set LP/LN. On the contrary, with a 
small   in random walk algorithm, the flows are likely to flow out of the seed 
nodes and spread to nodes far away from seeds, therefore those nodes near to seeds 
are likely to gain relatively lower scores to be assigned to weak negative set WN. 
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When fixing parameters N = 1000, K = 5, we are able to obtain higher F-measure 
value with increasing value of  , as shown in Table 4.7. Biologically, this is 
reasonable since unlabeled genes which share various biological evidences with 
labeled ones more likely belong to same class, either disease genes or non-disease 
genes. 
Table 4.7: Effect of parameter   (in random network propagation) to classification 
performance 
Parameter   Precision (p) Recall(r) F-measure (F) 
0.6 66.5% 82.3% 73.5% 
0.7 70.4% 82.5% 76.0% 
0.8 72.4% 81.0% 76.5% 
0.9 73.0% 79.7% 76.2% 
These results showed that PUDI was insensitive to the specific values of N and Q. 
In addition, the best performance was obtained when   = 0.8 which coincided with 
the recommended value by [22]. 
Fourthly, we investigated the capability of our proposed algorithm to detect disease 
genes for specific disease classes/groups – this is much more practically useful than 
predict general disease genes, e.g. developing novel drugs to tackle disease genes 
associated with a specific disease for pharmaceutical industry. In this work, we 
chose all disease classes [31] which have at least 20 confirmed disease genes and 
we obtained 8 specific disease classes in total. Here we listed the results for 8 
specific disease classes. Taking the two disease classes: cardiovascular and 
endocrine diseases as examples, we selected the disease genes containing the title 
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‘cardiovascular’ or ‘endocrine’ in the causative disease phenotype descriptions from 
GENECARD and OMIM. A total of 107 cardiovascular disease genes and 81 
endocrine disease genes are collected respectively (both treated as positive set P). 
Then, 10 groups of unlabeled gene sets are randomly selected from all gene set as 
the 10 unlabeled sets U (U has the same size with P, i.e. |P|=|U|). Again, all the 
approaches are evaluated on the identical groups of test data. Given that we have 
relatively small number of disease genes, to avoid tiny partitions, we performed 
3-fold cross validation for each of the 10 training groups and reported the average 
results in Table 4.8. 
Table 4.8: The performance comparison of six disease classes 
 
Diseases Number Method F-measure AUC 
Cancer 210 PUDI 72.4% 0.806 
ProDiGe 69.5% 0.708 
Smalter’s method 66.6% 0.778 
Xu’s method (1) 63.7% ~ 
Cardiovascular 107 
PUDI 80.4% 0.845 
ProDiGe 69.3% 0.703 
Smalter’s method 70.6% 0.723 
Xu’s method (1) 65.4% ~ 
Endocrine 81 
PUDI 79.2% 0.801 
ProDiGe 69.3% 0.701 
Smalter’s method 66.5% 0.733 
Xu’s method (1) 68.0% ~ 
Metabolic 263 PUDI 82.4% 0.897 
ProDiGe 69.3% 0.668 
Smalter’s method 69.6% 0.728 
Xu’s method (1) 71.4% ~ 
Neurological 217 PUDI 76.3% 0.843 
ProDiGe 68.1% 0.646 
Smalter’s method 63.1% 0.753 
Xu’s method (1) 63.0% ~ 
Nutritional 22 PUDI 72.7% 0.754 
ProDiGe 66.4% 0.695 
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Smalter’s method 69.4% 0.769 
Xu’s method (1) 65.6% ~ 
Ophthalmological 163 PUDI 74.9% 0.842 
ProDiGe 66.6% 0.647 
Smalter’s method 55.6% 0.758 
Xu’s method (1) 58.8% ~ 
Psychiatric 26 PUDI 69.2% 0.751 
ProDiGe 65.5% 0.734 
Smalter’s method 66.1% 0.742 
Xu’s method (1) 55.7% ~ 
Table 4.8 shows that our proposed PUDI algorithm is 9.8% and 9.9% better than the 
best results from Smalter’s method, Xu’s method and ProDiGe method for 
cardiovascular and endocrine diseases respectively. For Xu’s method, we have also 
tried different K valued from 1 to 21. It achieved the best results 72.1% with K=17 
for cardiovascular disease and 68.0% with K=1 for endocrine disease in terms of 
F-measure. 
We observed ProDiGe performs 1.3% worse than Smalter’s method for 
cardiovascular disease but 1.3-2.8% better than Xu’s method and Smalter’s method 
for endocrine diseases, showing that it cannot achieve consistently better results 
than other methods. As we mentioned earlier, since the subsets RS that are 
randomly selected from U may still contain unknown disease genes, it will affect 
the performance of individual classifiers built using P and RS as well as the final 
aggregated classifier. On the other hand, our proposed PUDI method partitions U 
into four label sets, so that the multi-level Weighted SVM classifier, can better 
exploit U as training sets by taking the varying confidence levels of the training sets 
into consideration. 
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Figure 4.3: ROC curves on eight disease groups 
ROC curve plots are drawn in Figure 4.3 and corresponding AUC from Table 4.8, 
indicating that PUDI outperform ProDiGe, and Smalter’s method on most of eight 
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disease groups. Since Xu’s method did not provide score measures for ranking 
genes for ROC curves, we were not able to compare this method with others. 
 
Figure 4.4: Comparison between PUDI and Transductive SVM 
PUDI is a semi-supervised algorithm in which unlabeled data is exploited to 
improve the classification performance. To evaluate the efficiency of unlabeled data 
exploration, PUDI is compare with an existing semi-supervised learning technique, 
namely Transductive SVM on six disease groups. The comparison result in terms of 
F-measure in Figure 4.4 shows that PUDI consistently outperforms Transductive 
SVM, indicating that PUDI is effective to utilize unlabeled data for disease gene 
identification. 
Table 4.9: Predicted novel disease genes using all confirmed genes 
Genes Prob Relevant Disease 
GP5 99.2% Bernard-soulier syndrome 
Gray platelet syndrome 
Platelet disorder 
Autoimmune thrombocytopenia 
Coagulopathy 
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Thrombocytopenia 
ALG13 97.9%  
ADPRHL1 96.7%  
PARVA 96.6% Tumors 
Cancer 
ODAM 96.4%  
ANGPTL1 96.3% Melanoma 
Tumors 
PTK7 96.1% Panic 
Panic attacks 
Panic disorder 
Premenstrual dysphoric disorder 
Effects cardiovascular 
Agoraphobia 
Anxiety disorders 
WSB1 95.7% Neurobalstoma 
AFF1 95.0% Lymphoblastic leukemia acute  
Acute leukemia 
Leukemogenesis 
Leukemia 
Chromosomal aberrations 
INHBB 94.7% Tumors 
MAPK12 94.4% Shock 
PHLDA1 94.3% Tumors 
CABLES2 94.0%  
BDH2 94.0%  
CD97 94.0% Thyroid carcinoma 
Thyroid carcinoma anaplastic 
Arthritis reactive 
Colorectal tumors 
Colorectal carcinoma 
SLC29A4 93.9%  
FAIM 93.8% Leukemia, lymphocytic, Acute 
EIF2AK2 93.8% Virus infection 
Vesicular stomatitis 
Hepatitis c 
Influenza 
Herpes simplex 
KRT20 93.7% Carcinoma merkel cell 
Carcinoma mucinous 
Adenocarcinoma 
ITGB1BP2 93.7% Cardiac hypertrophy 
Hypertrophy 
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Fifth, we applied PUDI for uncovering novel disease genes. This is different from 
the evaluations above where we performed cross validations, i.e. we used part of the 
confirmed disease genes as the positive training set, and the remaining confirmed 
disease genes as positive test set. Here, we attempted to discover putative disease 
genes that are not presented in the current confirmed disease gene dataset. In other 
words, we will exploit all the confirmed disease genes to predict novel disease 
genes. As a case study, we applied our PUDI algorithm to discover novel disease 
genes for cardiovascular diseases. Our algorithm detected 10 unlabeled genes that 
were not in benchmark/confirmed disease gene dataset. We then performed 
literature search to check if any of these putative disease genes predicted is indeed 
associated to cardiovascular diseases. We found that four of the predicted disease 
genes, namely, ATF4, MBNL1, NCKAP1 and CXCL14, have been reported to be 
related to cardiovascular diseases. For ATF4, it has been verified to play an 
important role in cardiovascular diseases using reverse transcription/real-time 
polymerase chain reaction and western blotting [114]. For MBNL1, it exhibited a 
regionally restricted pattern of expression in canal region endocardium and 
ventricular myocardium during endocardia cushion development in chicken [115]. 
Also, mutations of NCKAP1 showed specific morphogenetic defects: these mouse 
failed to close the neural tube, also failed to form a single tube (cardia bifida), and 
showed delayed migration of endoderm and mesoderm [116]. In addition, for 
CXCL14, it enhanced the insulin-induced tyrosine phosphorylation of insulin 
receptors and insulin receptor substrate-1, suggesting that CXCL14 played a causal 
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role in high-fat diet-induced obesity, which was frequently associated with 
hypertension (one type of cardiovascular diseases) [117].  
We perform our proposed PUDI algorithm on endocrine disease and find that out of 
11 predicted disease genes, three novel genes associated with endocrine diseases: 
EPHB6, CAMK2D, HEC6. Methylation-specific polymerase chain reaction (MSP) 
of EPHB6 is associated with breast cancer that is an endocrine-related cancer. In 
fact, studying the EPHB6 MSP is helpful for the prognosis and/or diagnosis of 
breast cancer [118]. Calmodulin and calmodulin-dependent protein kinase II 
(CaMKII) plays important rules in neuroendocrine cell. In Lu et al. [119], CaMKII 
negatively contributes to the regulation of parathyroid hormone (PTH) secretion via 
a pathway. Finally, HEC6 has medical implication in metastatic neuroendocrine 
prostate cancer, breast cancer and metastatic colon carcinoma. 
Furthermore, we performed our PUDI algorithm using all the confirmed disease 
genes as positive training set P (not focus on 1 specific disease). We predicted 1110 
novel disease genes and we selected the top 20 genes based on their SVM 
probabilities (we transformed the outputs from SVM into probabilities). Based on 
the literature search, the results in Table 4.9 show that 14 out of 20 (70%) predicted 
disease genes are indeed associated with one or more diseases. 
Then, we will discuss the time complexity of various computational methods for 
disease gene prediction and then show the actual time spent by each individual 
methods. We compare the time complexity of the new approach PUDI with three 
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existing methods, namely ProDiGe, Smalter’s method and Xu’s method. 
PUDI, ProDiGe and Smalter’s method are all SVM-based approaches and the 
training time complexity of SVM is O(N
2
) where N is number of training samples. 
For PUDI, it needs three additional steps: (i) to extract RN (with time complexity 
O(N)), (ii) to construct a gene similarity matrix and a gene similarity network (with 
time complexity O(N
2
)), and (iii) to run a random walk algorithm to extract LN, LP 
and WN. According to [120], Step (iii) has time complexity O(w*N
2
) in which w is 
number of iterations to converge. However, since w is typically very small (in our 
experiments w=20) compared to N, O(w*N
2
) can be reduced to O(N
2
). As such, the 
overall time complexity of PUDI is still O(N
2
). Similarly, the additional steps in 
ProDiGe and Smalter’s methods do not increase their time complexity as well, so 
they still end up with an overall time complexity of O(N
2). Although Xu’s method is 
based on KNN algorithm, which classifies each target gene based on its similarities 
to all the other genes in the training set, the complexity of KNN algorithm is also 
O(N
2
). In summary, all the tools have exactly the same time complexity. 
Next, we compare the actual running times using different tools across different 
disease groups.  All the experiments were performed on the same machine with 
1.83GHz CPU and 1GB (987MHz) memory. 
Table 4.10: Speed comparisons using three algorithms 
Disease Group NO. of Samples Approaches Time (s) 
Cardiovascular disease 
210 PUDI 15.410 
210 ProDiGe 13.328 
210 Smalter’s method 14.953 
 100 
 
Metabolic disease 
526 PUDI 45.578 
526 ProDiGe 34.000 
526 Smalter’s method 41.015 
Neurological disease 
434 PUDI 40.486 
434 ProDiGe 32.538 
434 Smalter’s method 34.75 
Ophthalmological disease 
214 PUDI 17.316 
214 ProDiGe 14.11 
214 Smalter’s method 16.078 
Cancer disease 
350 PUDI 29.075 
350 ProDiGe 22.391 
350 Smalter’s method 24.116 
Table 4.10 shows the actual running time for the three SVM-based methods. First, 
we observe that PUDI did spend 10%-20% more time than ProDiGe and Smalter’s 
method (see also Figure 4.5), as it needed to perform a number of steps before 
building the multi-level SVM classifier. However, we also notice that the additional 
time spent was quite small, i.e. only a few more seconds for all the disease groups, 
and with that our PUDI was able to achieve at least 10%-20% improvement in 
terms of F-measure than the other existing methods on most of the specific disease 
gene groups. Furthermore, once the final classifiers are built, the efficiency of 
prediction procedures is more or less same among all these methods. As such, our 
PUDI method which can provide more accurate prediction is certainly preferable. 
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Figure 4.5: Running time using different algorithms 
Parameter Setting in Weighted SVM 
For Multi-level SVM, we set its penalty factors in following way: let SVM penalty 
factors     
   , and   
    
    
   ,   
     
     
   ,   
  
  
    
   ,   
     
     
   , then we can get an optimizing goal function 
using formula 32:  
 ,   
  ,   
 , and   
   are used as weights for training sets 
P, LP, RN, and LP respectively. The weight for WN equals one in equation 32. Let 
Ψ denote the weight vector as (  
 ,  
  ,  
 ,  
  ), we vary c and Ψ to obtain the 
empirical best parameter through 10 fold cross validation on whole disease gene set 
(3 fold cross validation on particular disease gene set), i.e. try different parameter 
values using the 9 fold training data and compute the classifiers’ performance using 
the remaining 1 fold validation set. The parameter values with the best average 
results will be set the final parameters values.    
In particular, we vary c with    ,    ,    , …,     , and vary Ψ in following 
ways: Ψ is initialized by (1, 1, 1, 1), and then vary each w of Ψ by turns while 
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keeping other w (w Ψ)  stable. Firstly, we vary   
  from    ,    ,    , …,  , 
and we obtain the empirical optimal value    for   
 . Then, we vary   
   with 
   ,    , …,  , which guarantee the weight of LP is lower than that of P. After 
turning parameters   
  and   
   for positive weights, we vary   
  and   
   
respectively following the same step as   
  and   
   in the range of    , 
   , …,  . We discover that it is good enough to tune   
  and   
   in this 
range from our multiple experimental trials. For each parameter in weight vector, 
the maximal turning time is (b+6). The turning times for our weight vector are no 
more than 4*(b+6). In summary, we set the values for   
 ,   
  ,   
 ,      
   
in turn so that they can achieve best average performances using cross validation 
experiments. 
We used the criteria of Weight SVM parameter tuning procedure in [108]. In our 
experiments on general disease gene identification, we found that we could obtain 
the best performance when parameter C was around 256,   
  from 1.1 to 1.9, 
  
   and   
   from 1 to 1.1, and   
  from 1.1 to 1.2 (note we can run a 
number of times cross-validation to get the average values). For example, one best 
performance for general disease gene identification was achieved when C = 256, 
  
 =1.5,   
 =1.2,   
  =1 and   
  =1.1. We show the actual procedure for 
parameter tuning below: 
Algorithm 4.2 The procedure of parameter tuning in PUDI 
1. Initialize (  
 ,  
  ,  
 ,  
  ) by (1,1,1,1); 
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2. Vary C with    ,    ,    , …,           to get best result using 
cross-validation.  
3. Vary   
  from    ,    ,    , …,   to obtain optimal value    for   
 ; 
4. Vary   
   with    ,    , …,  , to obtain value   
 
,     ; 
5. Vary   
  and   
   respectively following the same step (3 and 4) as   
  
and   
  . 
4.4 Summary 
To identify disease genes, traditional machine learning methods typically build a 
binary classification model using confirmed disease genes as positive set P and 
unknown genes as negative set N. The negative set N is noisy because the unknown 
gene set U contains some unknown disease genes. As such, the classifiers built do 
not perform as well as they could have. 
In this work, we have proposed a novel PU learning approach PUDI for disease 
gene prediction. We introduced a new feature selection method to identify the 
discriminating features and performed a further partitioning of the unlabeled set U 
into multiple training sets for a more refined treatment of U to build the final 
classifier. We found that PUDI could better model the classification problem for 
disease gene prediction as it achieved significantly better results than the 
state-of-the-art methods. Given that many machine learning problems in biomedical 
research do involve positive and unlabeled data instead of negative data, we believe 
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that the performance of machine learning methods for these problems can possibly 
be further improved by adopting a PU learning approach [121] [36], as we have 
done here for disease gene identification. For future work, we will consider to 
integrate more biological resources [122], such as gene expression data etc. In 
addition, we may explore more complicated machine learning methods to better 
model the positive and unlabeled data distributions. 
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Chapter 5.  
Ensemble based Positive Unlabeled 
Learning for Disease Gene Identification 
Identifying the association between human genetic diseases and their causative 
genes has significant impact to healthcare. With the rapid development of 
biomedical research, increasing numbers of genes have been confirmed as causative 
genes to diseases. Machine learning methods can be applied to discover new disease 
causative genes based on their genetic associations to those confirmed disease 
causative genes. Particularly, positive unlabeled learning (PU learning) methods 
have been recently proposed to build a classification model where the causative 
genes are treated as positive training set P and unknown genes are treated as 
unlabeled set U (instead of negative set N) as unknown genes contain undiscovered 
disease causative genes.  
In this chapter, we investigate how to integrate multiple biological sources, 
including phenotype similarity, gene ontology, protein domain, gene expression, 
and protein interactions, to extract potential positive and negative sets with 
corresponding confidence scores from unlabeled set U, for building a number of PU 
learning classifiers. In addition, we have also designed a novel ensemble-based PU 
learning method EPU to integrate multiple PU learning classifiers for more accurate 
and robust disease gene prediction. We observe that EPU has achieved significant 
better results compared with the state-of-the-art methods as well as individual PU 
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learning classifiers across six disease groups. Through integrating the outputs of 
several PU learning classifiers, we are able to minimize the potential bias and risk 
of individual predictions, so that the expected errors by our ensemble approach can 
be expected to be largely reduced. 
The proposed EPU method is effective to integrate multiple biological data sources 
and numerous computational classifiers for disease gene prediction. Given that 
more reliable biological data sources and powerful computational classifiers will be 
available in the future, we can expect that our EPU method can be further improved 
by integrating these additional high-quality biological sources and computational 
methods. 
5.1 Introductory 
Identification of interaction between phenotype and its causative genes is a crucial 
part of healthcare. In recent years, a large number of biological data sources are 
available by high throughput experiments. This provides an invaluable resource for 
developing machine learning methods to identify novel disease genes on various 
types of biological datasets. 
Recent studies have revealed that genes associated with similar disorders have been 
shown to demonstrate higher probabilities of similar gene expression profiling [123], 
high functional similarities [124] [125] and physical interactions between their gene 
products [126] [127]. In addition, with disease phenotype similarity data, genes 
associated with same/similar disease phenotypes are likely to share similar 
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biological functions. Given a phonotype, we can infer its potential disease genes 
from those disease genes associated with other similar phenotypes [128]. From 
DNA sequence, proteins involved in hereditary diseases tend to be long, with more 
homologs with distant species, but fewer paralogs within human genome [129]. 
Furthermore, disease genes associated with similar disease phenotypes are likely to 
attach together to be a functional modules, such as protein complexes, pathways 
[130]. 
A number of methods above have been proposed to prioritize candidate genes based 
on different kinds of biological data, such as gene sequence data, gene expression 
profile, evolutionary features, functional annotation data and PPI dataset. Adie et al. 
[131] employed a decision tree algorithm based on a variety of genomic and 
evolutionary features, such as coding sequence length, evolutionary conservation, 
presence, closeness of paralogs in the human genome, etc. In addition to sequence 
and evolutionary information, topological information on PPI network has been 
demonstrated to be useful for disease gene prediction. Smalter et al. [35] applied 
support vector machines (SVM) classifier using PPI topological features, 
sequence-derived features, evolutionary age features, etc. Radivojac et al. [101] first 
built three individual SVM classifiers using three types of features, i.e. PPI network, 
protein sequence and protein functional information, respectively. It then built a 
final classifier by combining the predictions from three individual classifiers for 
candidate gene prediction.  
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The research work mentioned above employed machine learning methods to build a 
binary classifier where the confirmed disease genes are used as positive training set 
P and unknown genes are used as negative training set N. However, since the 
negative set N contains unconfirmed disease genes (false negatives), these machine 
learning techniques do not perform well. Recently, positive unlabeled learning (PU 
learning) methods have been proposed to build a classification model where 
unknown genes are treated as unlabeled set U (instead of negative set N) as 
unknown genes contain undiscovered disease causative genes. For example, 
Mordelet et al. proposed a bagging method ProDiGe for disease gene prediction. 
This method iteratively chooses random subsets (RS) from U and trains multiple 
classifiers using bias SVM to discriminate P from each subset RS. It then 
aggregates all the classifiers to generate the final classifier [132]. As RS could 
contain less noise (unknown disease genes) than original set U, it performs better 
than standard binary classification models which directly use U as negative training 
data. More recently Yang et al. designed a novel multi-level PU learning algorithm 
PUDI to build a classifier for disease gene identification where unlabeled set U are 
partitioned into multiple positive and negative sets with confidence scores which 
can be used to enhance classifier building [133] [134]. 
In this chapter, we design a novel ensemble learning framework, called EPU 
(Ensemble Positive Unlabeled learning) for disease gene identification. We first 
extract multiple positive and negative samples from unlabeled set U through 
performing random network with restart algorithm on three networks, namely 
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protein interaction network, gene expression similarity network, and GO similarity 
network. Then, we build three independent PU learning models that utilize these 
extracted positive and negative samples as training data with different confidence 
scores. Finally, we design a novel ensemble strategy EPU via minimizing the 
overall error rate and giving different weights to different PU learning models. We 
have compared EPU with multiple state-of-the-art techniques, namely, multi-level 
example based learning [108], Smalter’s method [35], Xu’s method [135] and 
ProDiGe method [132]. The experimental results show that EPU outperforms the 
existing methods significantly for identifying disease genes on 6 disease groups. In 
addition, our proposed EPU algorithm also achieves better results compared to three 
individual PU learning classifiers, demonstrating that proposed ensemble-based 
approach is able to effectively utilize each of PU learning methods. We also conduct 
a case study to show how our proposed EPU algorithm can discover novel disease 
genes for endocrine and cancer diseases. 
5.2 Material and Method 
In this section, we begin with the description of the experimental data that we have 
used and briefly introduce how to build protein interaction network, gene 
expression similarity network, GO similarity network [25] [122] [136]. Then, in 
Section 5.2.1, we will present our proposed EPU algorithm, including how to learn 
multiple classification models, which learns an accurate classification model from 
the given positive set P and unlabeled data U. 
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5.2.1  Experimental data and gene network modeling 
In this section, we have exploited the following biological data, including human 
protein interaction data, gene expression data, gene ontology, and phenotype-gene 
association data. 
Human protein interaction data (PPI) is downloaded from the Human Protein 
Reference Database (HPRD) [137] and Online Predicted Human Interaction 
Database (OPHID) [138]. The combined PPI dataset contains 143,939 PPIs among 
a total of 13,035 human proteins. We build a protein interaction network GPPI = 
(VPPI , EPPI) where VPPI represents the set of vertices (proteins) and EPPI denotes all 
edges (detected pairwise interactions between proteins). GPPI can be represented as 
its matrix format, i.e. WPPI=[wij] where wij=1 if corresponding protein pairs 
            ; 0 otherwise. 
Gene expression data is obtained from RNASeq data which is made publicly 
available in the EBI ArrayExpress, by the Illumina Human BodyMap 2.0 project, 
obtained from: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE30611. 
The dataset comprises Fastq reads from the paired-end sequencing of cells from 16 
human tissue types, including colon, heart, kidney, white blood cells and so on, 
using the Illumina HiSeq next generation sequencing platform. This dataset 
represents the expression values of 17,652 human genes on 16 human tissue types. 
Suppose gene gi and gj are represented into their profile vectors (ei1, ei2,…, eis) and 
(ej1, ej2,…, ejs) respectively where eik (k=1, 2, …, s) denotes the expression value of 
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gene i from k-th tissue. Pearson correlation coefficient is employed to measure the 
similarity between gi and gj: 
             
                   
 
   
           
  
              
  
   
     (33) 
where     
 
 
    
 
   ,     
 
 
    
 
   . 
We build a gene expression similarity network              , where     
represents a set of genes occurred in the gene expression data and     represents a 
set of edges between the genes in    . Particularly, for each gene gi, we have a link 
between gi and gj if their similarity sim(ei, ej) is among the top 5 out of all the 
similarities between gi and other genes, which filter those low similar pairs and 
potential noise in gene expression data.  
Gene Ontology (GO, http://www.geneontology.org/) is a set of controlled 
vocabulary to annotate the attribution of genes and gene products [139]. Gene 
Ontology provides three sub-ontologies, namely, biological process (BP), molecular 
function (MF) and cellular components (CC) [139]. For each gene, we represent it 
into a feature vector where features include all the three sub-onotolgies, i.e. 
{MF1,…,MF|SMF|, BP1,…,BP|SBP|, CC1,…,CC|SCC|}. We then build GO similarity 
network              , where     is the gene set annotated in GO dataset and 
    is a set of edges between the genes in    . Similarly to the gene expression 
similarity network, for each gene, we keep those top 5 edges which have highest 
similarities.     can be represented as its matrix format, i.e. WGO=[wij] where  
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    (34) 
where Dis(gi, gj) denotes Euclidean distance between two gene vectors gi and gj. 
Note that 0≤ wij ≤1. 
Phenotype-gene association data: 4260 phenotype-gene association data spanning 
2659 known disease genes and 3200 disease phenotypes, is obtained from the latest 
version of OMIM (http://omim.org/) [140]. Goh et al. [126] further processed all the 
entries in OMIM database and categorized the 3200 disease phenotypes into 22 
disease groups/classes, i.e. Cancer, Metabolic, Neurological, Endocrine, etc, 
through the physiological system affected. For example, Endocrine disease group 
has 62 OMIM phenotypes, including OMIM 241850 (Bamforth-Lazarus syndrome) 
and OMIM 304800 (Diabetes insipidus, nephrogenic) etc. 
Phenotype similarity network: Disease phenotype similarity network [141], is 
defined as              , where     denotes the set of disease phenotypes 
and     denotes relevant phenotype pairs. Disease phenotypes in     are 
represented as feature vectors in which feature terms are Medical Subject Headings 
(MeSH) controlled vocabulary, and phenotype similarities in     are evaluated 
underline concept relevance and frequency of MeSH terms appeared in text 
description of OMIM documents. According to Vanunu, O. et al. [128], phenotype 
pairs with high similarities are regarded as relevant and stored in    . 
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Figure 5.1: Overall schema of EPU learning algorithm 
5.2.2.  The proposed Technique EPU 
The schema of EPU algorithm is present in Figure 5.1. EPU firstly selects candidate 
positives from positive genes and reliable negatives from unlabeled genes, then 
builds three gene similarity networks using PPI data, gene expression data and Gene 
Ontology data and applies random walk on three networks to weight confidences of 
unlabeled genes to positive/negative class. Secondly, we exploit these weighted 
genes to build three diverse classification models to predict “soft” labels for test 
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genes. Finally, considering the prediction results from three classifiers, an ensemble 
learning approach is applied to make a final decision for test gene class. 
Suppose all disease genes from OMIM are stored into a disease gene set DIS. Then, 
all the other genes without involving in DIS will be treated as unknown/unlabeled 
genes and stored into a set UG (contains 16, 570 genes) [142]. Note that each gene, 
both in DIS and UG, is represented as a feature vector, namely,               
where   is the total number of features from GO terms, protein domains and PPI 
topological features, following our previous work [133]. 
Now, we will elaborate how to predict novel disease genes given a particular 
disease or disorder. In particular, those confirmed disease genes for the given 
disorder group are treated as positive set P (P    ) and randomly selected 
unknown genes from UG are treated as unlabeled set U (            ), 
following the experimental settings in [131] [35] [135]. As we mentioned in 
introduction part, we will employ PU learning models for disease gene prediction. 
Step 1. Weighting unlabeled genes by integrating multiple biological evidences  
Given one specific disease class and its associated disease genes, we firstly 
prioritize candidate positives and reliable negatives based on their similarity to 
query disease class. Then we build three gene similarity networks using PPI, gene 
expression and GO as introduced in section 5.2.1, and perform a random walk with 
restart algorithm on three gene similarity networks to evaluate degree of unlabeled 
genes belonging to disease class or non-disease class. 
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Figure 5.2: Procedure of extracting candidate positive set 
Step 2. Extracting candidate positives and reliable negatives  
Typically, given positive set P is relatively small, we first want to find some 
positive candidate genes CP to complement original positive set P. Recent studies 
have revealed that similar phenotypes are often caused by functionally related 
disease genes [124] [126], suggesting we could find positive candidate genes CP 
through searching those genes associated similar/relevant phenotypes, by 
guilt-by-association principal. Particularly, given a disease group/class, we search 
its associated disease phenotypes, which serve as query phenotypes to uncover 
those similar disease phenotypes. Figure 5.2 shows the detailed procedure where 
Q1-Q3 are three disease phenotypes involving in current disease class (e.g. Cancer). 
We can find those similar phenotypes denoted by P1-P5 through Phenotype 
similarity network if they have a link, e.g. Q1 and P1 (thicker lines represent higher 
similarity). Known confirmed disease genes (denoted by g1-g5) associated with 
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similar phenotypes P1-P5 will be regarded as candidate positive genes.  
Now, we elaborate how to extract reliable negative gene set RN. Reliable negatives 
are those unlabeled genes are very different from positive set P. To extract RN, we 
build a “positive representative vector” (pr) by summing up gene vectors in P and 
normalizing it, following the work [133]. Then we compute average Euclidean 
distance [143] of every unlabeled gene    in U from pr. Finally, we regard an 
unlabeled gene    as a member of RN if its distance from pr is longer than the 
average distance (of all the genes in U) from pr, formalized as: 
                           (35) 
where            is the Euclidean distance between gene    and positive 
representative vector pr. Here we compute an average distance   of all the 
unlabeled gene in U from pr as:   
 
   
           
   
   . 
Step 3. Weighting unlabeled genes by performing label propagation on 
multiple networks 
At this point, we have the given positive set P, a candidate positive set CP, a 
reliable negative set RN and a remaining unlabeled set        . In order to 
build a good classification model, we need to extract those examples/genes with 
reliable labels which are near the decision boundary between the actual positive and 
negative class. In this chapter, Random Walk with Restart algorithm [144] is 
adapted to perform flow propagation which spreads the label information from P, 
 117 
 
CP and RN to those unlabeled genes in    on the three networks we have 
constructed, namely a PPI network     , a GO similarity network     and a gene 
expression similarity network    . 
Formally, let    be an initialization vector where primitive scores are assigned to 
all genes in three networks, which indicate genes’ potential label information. Let 
  ,   
  and    denote the initial values for genes in  , CP and RN respectively. 
Particularly, all the genes      are given a score          , indicating their 
disease gene status. For each candidate positive gene      , a score   
      
                                       is assigned to it (where        denotes 
disease phenotypes caused by gene   ,       denotes disease phenotypes caused 
by disease set P), i.e. its maximal phenotypic similarity to the known disease genes 
in P. The higher the maximal phenotypic similarity to the known disease genes, the 
more reliable a gene in CP belongs to the disease/disorder class. On the other hand, 
for genes in reliable negative set RN, to balance total amount of flows between 
positive genes and negative genes,                         
            
    . Note that remaining unlabeled genes in   are assigned a score 0 temporally 
and we will perform flow propagation and assign them the final scores.  
For each of our three networks     ,     and    , the prior influence from seed 
nodes in P, CP and RN, are first distributed and pumped to their direct neighbors, 
which continue to spread the influence flows to other nodes iteratively across the 
whole network. Given    be the initial score vector (step 0),   , the score vector 
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at step t, can be calculated as follows: 
                            (36) 
where       and    
    is a normalized format of matrix  ,   
              . Here   is the diagonal matrix and          .   represents 
the percentage of flow back to original seed nodes in P, CP and RN during each 
iteration of propagation. Default value of   is set as 0.7, following the papers in 
[25] [133] [130]. 
Eventually, the information flow will converge to steady state [144]. In our case, the 
Random Walk with Restart algorithm will stop its iterative process when difference 
between two steps    and      is less than   
   [25], measured by L1 norm. 
Finally, unlabeled gene scores, calculated from three gene networks respectively, 
are combined into one integrated score: 
             
 
 
                                  (37) 
where           ,           and           are gene   scores in PPI 
network, GO similarity network and gene expression similarity network 
respectively. 
5.2.3  Ensemble positive unlabeled learning EPU 
Given two classes C = {+, -}, where ‘+’ denotes positive/disease class and ‘-’ 
presents negative/non-disease class, we have built three classification models, 
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including Support Vector Machine, K-Nearest Neighbor and Naïve Bayes classifier, 
to classify genes into positive and negative class.  
PU learning model 1: Multi-level Support Vector Machine (MSVM) Based on the 
integrated score             , we further partition the unlabeled genes      
  ) into three parts: likely positive set LP (genes get higher positive integrated 
scores), likely negative set LN (genes get lower negative integrated scores) and 
weak negative set WN (remaining genes) using the following criteria: 
      
                                                         
                                                     
                                     
      (38) 
Finally, a multi-level classifier is built based on positive training set P, reliable 
negative set RN, and three newly generated sets LP, LN, and WN, via weighted 
support vector machine technique [106] [107], to take into account of the inherently 
different levels of trustworthiness of labels in the five gene set.  
The objective function of Weighted SVM can be defined as [108]: 
          
 
 
       
          
            
            (39) 
               
           
            
Subject to:             
                        
Where the values of parameters   
 ,   
  ,    
 ,    
   and   
    can be decided by using 
cross-validation techniques. Finally, we apply our MSVM model 
                   to classify test gene     which indicates its probability 
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with respect to class    (     . 
Note here we did not use candidate positive set CP directly. However, together with 
P, it has been used for choosing those likely positive genes in LP through 
propagating their influence across three networks.  
PU learning model 2: Weighted K-Nearest Neighbor (WKNN): KNN is an instance 
based learning method, which classifies a test unknown example/gene based on the 
class labels of its top K nearest training examples, i.e. majority class vote of its 
nearest K neighbors. The distance between the test gene and other training examples 
can be computed using some common distance metrics such as Euclidean distance. 
Given a test gene gi and its k nearest neighbor set   , we divide    into positive 
and negative training subsets, namely                             and 
                            based on these neighbors’ integrated scores. 
The conditional probability of the test gene gi with respect to disease (+) 
/non-disease class (-), is measured as 
              
                      
                   
  , 
                           
                      
                   
      (40) 
Note that the weighted KNN accumulated positive integrated scores and negative 
integrated scores and then the probability belonging to positive (or negative) class is 
propositional to their accumulated scores. 
PU learning model 3: Weighted Naïve Bayes (WNB): Given a test gene   , 
 121 
 
according to Bayes' theorem, the probability that gene    belongs to a class cj 
(            ) can be computed as: 
                 
                 
     
    (41) 
where the probability       is a constant for the positive and negative classes. The 
prior probabilities of positive and negative class are defined as 0.5, i.e.     
             . Given a gene vector               , the conditional 
probability of feature    associated with class   , denoted as           , is 
calculated as: 
           
                        
                         
 
   
    (42) 
where       is value of feature    in gene vector   ,     is defined as either 
                        or                        , depending 
on cj is positive class + or negative class  .  
Finally, assuming that the probabilities of features are independent given the class cj, 
we obtain the Naïve Bayes classifier: 
                 
                        
 
   
                         
 
   
   
   
   (43) 
Ensemble-based algorithm for integration of individual classifiers 
Note we can apply the three classification models constructed above to classify each 
unlabeled genes as disease or non-disease gene individually. In this section, in order 
to perform more robust classification, we design a novel ensemble learning model 
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to integrate these models. The performance of our proposed ensemble model is 
evaluated via three fold cross validation. Particularly, we partition the genes in P 
and U into three folds where two folds are used for training set D and the remaining 
one fold is used for test set T. We perform the experiments for three times and we 
report the average results in terms of F-measures as the evaluation metric.  
Suppose     =              denotes probability value of gene    with respect 
class c predicted by individual classifier j
th
. All genes in D can be organized as the 
following matrix: 
 
       
   
           
             (44) 
where     is the number of individual classifiers and     is the size of training 
set  . 
Next, we train our ensemble model       , to integrate multiple classification 
models, which can be denoted as follows: 
                           
                            
            
 (45) 
where     is a weight vector that indicates the importance of individual models. The 
final output value “1” denotes disease/positive class and ‘-1’ denotes 
non-disease/negative class. 
Next, we elaborate how to learn the classifier weight     from training set D. We 
define        as training error of the hypothesis of our ensemble model: 
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         (46) 
where    (         ) and    (         ) are the actual class and predicted 
class by our ensemble model for training gene    respectively.        is a linear 
square error function that evaluates the difference between    and   . We 
minimize        to guarantee the classification output   with minimal error rate 
and calculate the weight vector     .  
Here, Gradient decent is applied to search the probable weight vectors in error 
surface. The gradient of   for    , denoted as          
  
   
 
  
   
   
  
   
 , is the 
derivative of   with respect to each component of the vector    . From above 
equation, we could get each component of         as follows: 
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The training rule of gradient descent is to guarantee     is changed in direction that 
moves to steepest descent along the error surface:             , where      
         .   is a small positive constant, called learning rate, to determine the step 
size in gradient decent exploration. We set        , following previous work 
[145]. The negative gradient          gives the direction of steepest decrease. 
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According to equations above, we update the gradient descent rule, as: 
      
  
   
                     (48) 
The overall ensemble learning method is described in Algorithm 5.1: we first pick 
up an initial random weight vector for    . The ensemble model is applied to all 
training genes and compute     for each weight of individual classifiers according 
to equation (   ) above. Each weight is then updated by adding    . This process 
is repeated until     converges. When   is a large number, the search exploration 
might overstep the minimum point in the error surface rather than settling into it. 
Therefore, the value of   is supposed to be gradually reduced as the number of 
gradient descent grows. 
Algorithm 5.1 Ensemble based Positive Unlabeled learning algorithm 
1. Initialize each element in weight vector     with a small random real number; 
2. Do following operations until     converges: 
3.    Initialize each      ; 
4.    For each decision vector <   ,y> in training samples, Do: 
5.        compute output       ; 
6.        For each linear unit weight   , Do: 
7.                            
8.    For each    in    , Do: 
9.                 
10.    Record the weight vector as optimal vector; 
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11. Predict the class of test samples using                           
5.3 Experimental Results 
In this section, we begin with introduction about experimental setting and 
evaluation metrics. Then we present the experimental results, including the 
comparisons of our proposed EPU algorithm with four state-of-the-art techniques 
for disease gene prediction, including PUDI method [133], Smalter’s method [35], 
Xu’s method [135] and ProDiGe [132]. In addition, we also compare with three 
individual component classifiers, namely, MSVM, WKNN and WNB. Finally, we 
also compare EPU with existing ensemble model and perform novel disease gene 
prediction. 
5.3.1  Experimental setting 
From the 22 specific disease classes [126], we choose six largest disease classes 
with at least 50 confirmed disease genes, which allows us to build classification 
models as well as for evaluation purpose. The table 5.1 lists number of disease 
genes for six disease/disorder classes, including cardiovascular disease, endocrine 
disease, cancer disease, metabolic disease, neurological disease, and 
ophthalmological disease. Given a particular disease, its disease genes are treated as 
positive set P, and the unlabeled set U is randomly selected from all the unknown 
genes, with a balanced set        , following the setting in [131] [35] [135]. To 
avoid bias sampling, 10 groups of unlabeled set U are randomly selected. Note all 
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approaches build classification models and evaluate performance on the identical 
groups of training and test data. 
Table 5.1: Number of disease genes associated six specific diseases 
Disease 
category 
cardiovascu
lar 
Endocri
ne 
metaboli
c 
neurologic
al 
ophthalmologic
al 
cance
r 
No. of 
gene 
samples 
107 81 263 217 163 210 
 
5.3.2  Evaluation metrics 
In this study, we adopt the precision, recall and F-measure to measure the 
performance of the classification model on six specific disease classes. The 
F-measure is the harmonic mean of precision (denoted as  ) and recall (denoted as 
 ), defined as 
    
   
   
        (49) 
Therefore, F-measure indicates an average effect between precision and recall, and 
F-measure is large only when both of   and   are good, is small when either of 
them is poor. This is suitable to our objective to accurately predict disease genes in 
each disease class. Having either too small a precision or too small a recall is 
unacceptable, and reflecting a low F-measure. 
Note that we will compute the F-measure for all six disease gene classes and report 
the average F-measure base on 10 groups of training sets of each disease class. 
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5.3.3  Experimental result 
Compare our EPU ensemble learning algorithm over state-of-the-art 
techniques 
Firstly, we compared our ensemble-based algorithm with four state-of-the-art 
techniques, namely, PUDI method [133], Smalter’s method [35], Xu’s method [135] 
and ProDiGe [132] for specific disease/disorder group gene classification. 
Table 5.2 shows that our proposed EPU, in average, is able to achieve 6.5%, 15.1%, 
16.2% and 16.4% better than PUDI, ProDiGe, Smalter’s method, Xu’s method in 
terms of F-measure. Particularly, when we compare with PUDI, a recently proposed 
method, our EPU can achieve much better precision and consistently better recall. 
These results indicate that our EPU method can effectively extract hidden positive 
and negative data from unlabeled data, which in turn boost the performance of our 
EPU algorithm. 
Table 5.2: Overall comparison among different state-of-the-art techniques 
Disease group Techniques Precision (p) Recall 
(r) 
F-measure 
(F) 
Cardiovascular PUDI 0.820 0.803 0.804 
ProDiGe 0.543 0.963 0.693 
Smalter’s method 0.754 0.676 0.706 
Xu’s method 0.721 0.600 0.654 
EPU 0.852 0.810 0.841 
Endocrine 
PUDI 0.836 0.753 0.792 
ProDiGe 0.573 0.877 0.693 
Smalter’s method 0.764 0.588 0.665 
Xu’s method 0.754 0.620 0.680 
EPU 0.881 0.877 0.879 
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Neurological 
PUDI 0.703 0.801 0.749 
ProDiGe 0.631 0.740 0.681 
Smalter’s method 0.606 0.659 0.631 
Xu’s method 0.597 0.667 0.630 
EPU 0.782 0.804 0.786 
metabolic PUDI 0.801 0.848 0.824 
ProDiGe 0.587 0.845 0.693 
Smalter’s method 0.591 0.847 0.696 
Xu’s method 0.656 0.783 0.714 
EPU 0.833 0.939 0.909 
ophthalmological PUDI 0.716 0.785 0.749 
ProDiGe 0.583 0.777 0.666 
Smalter’s 
method 
0.567 0.778 0.655 
Xu’s method 0.642 0.713 0.674 
EPU 0.893 0.810 0.847 
cancer PUDI 0.763 0.800 0.780 
ProDiGe 0.711 0.798 0.753 
Smalter’s 
method 
0.738 0.790 0.763 
Xu’s method 0.710 0.797 0.751 
EPU 0.812 0.845 0.826 
Average 
performance 
PUDI 0.773 0.798 0.783 
ProDiGe 0.605 0.833 0.697 
Smalter’s 
method 
0.670 0.723 0.686 
Xu’s method 0.680 0.697 0.684 
EPU 0.842 0.848 0.848 
Compare our EPU method with individual component classifiers 
In this subsection, we compared the performance among 4 techniques, including 3 
individual component classifiers MSVM, WNB, WKNN and our proposed EPU. As 
shown in Table 5.3, in average, MSVM achieves the highest F-measure (81.3%), 
much higher than WNB (69.5%) and WKNN (68.7%). This is not surprising as 
MSVM can take multiple positive and negative sets with different confidence scores 
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into consideration for building its classification model. Furthermore, SVM has 
performed significantly better than NB and KNN in many real-world applications.  
In addition, comparing our ensemble learning method EPU with the three individual 
component classifiers, we observe that EPU is able to achieve 84.8% in terms of 
F-measure, which is 3.5%, 15.3% and 16.1% better than MSVM, WNB, WKNN 
respectively. This is because our proposed EPU can effectively integrate multiple 
classification models and minimize the overall error rate of our final ensemble 
classifier via dynamically assigning different weights to different classification 
models. 
Table 5.3: Overall comparison to single-expert classifiers 
Disease group Techniques Precision (p) Recall (r) F-measure (F) 
Cardiovascular MSVM 0.743 0.876 0.804 
WNB 0.573 0.725 0.639 
WKNN(3) 0.601 0.686 0.640 
EPU 0.852 0.810 0.841 
Endocrine 
MSVM 0.834 0.852 0.842 
WNB 0.613 0.704 0.653 
WKNN(3) 0.645 0.531 0.579 
EPU 0.881 0.877 0.879 
Neurological 
MSVM 0.693 0.837 0.758 
WNB 0.611 0.744 0.670 
WKNN(3) 0.623 0.671 0.646 
EPU 0.782 0.804 0.786 
Metabolic MSVM 0.840 0.913 0.874 
WNB 0.688 0.799 0.739 
WKNN(3) 0.766 0.788 0.776 
EPU 0.833 0.939 0.909 
ophthalmological MSVM 0.784 0.861 0.819 
WNB 0.612 0.787 0.688 
WKNN(3) 0.673 0.722 0.696 
EPU 0.893 0.810 0.847 
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Cancer MSVM 0.734 0.839 0.783 
WNB 0.725 0.851 0.783 
WKNN(3) 0.764 0.810 0.786 
EPU 0.812 0.845 0.826 
Average 
performance 
MSVM 0.786 0.863 0.813 
WNB 0.637 0.768 0.695 
WKNN(3) 0.679 0.701 0.687 
EPU 0.842 0.848 0.848 
Comparing EPU with existing ensemble learning approach 
We compare our EPU with two ensemble baselines, one is to adopt a uniform 
combination of the three models trained individually, the other applies a weighted 
combination based on accuracy of component models. Table 5.4 performs 
evaluation of three ensemble approaches on six disease groups, and EPU 
consistently outperforms other ensemble methods significantly, which indicates 
either uniform or weighted combination is unable to balance component classifiers 
with proper weights. Uniform combination (UComb) has the worst performance 
due to equally weighting all components for any disease group evaluations. On the 
other hand, weighted combination (WComb) roughly equates single classifier 
scenario with that in ensemble classifiers. Unlike above two approaches, EPU uses 
Gradient decent to optimize the weights of each component classifiers under each 
disease group, which specifies the weights corresponding to different disease 
groups. 
Table 5.4 Number of disease genes associated with six disease classes 
Disease group Techniques Precision (p) Recall (r) F-measure (F) 
Cardiovascular Wcomb 73.7% 87.3% 80.0% 
Ucomb 56.3% 80.0% 66.0% 
EPU 85.2% 81.0% 84.1% 
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Endocrine 
Wcomb 86.1% 84.0% 85.0% 
Ucomb 65.5% 73.3% 67.9% 
EPU 88.1% 87.7% 87.9% 
Neurological 
Wcomb 69.6% 83.5% 75.9% 
Ucomb 65.3% 74.7% 70.0% 
EPU 78.2% 80.4% 78.6% 
Metabolic 
Wcomb 86.6% 92.5% 89.5% 
Ucomb 68.4% 89.1% 77.4% 
EPU 83.3% 93.9% 90.9% 
Ophthalmological 
Wcomb 76.9% 87.3% 81.8% 
Ucomb 59.4% 78.7% 67.7% 
EPU 89.3% 81.0% 84.7% 
Cancer 
Wcomb 78.7% 80.3% 79.5% 
Ucomb 69.7% 93.7% 79.9% 
EPU 81.2% 84.5% 82.6% 
Average 
performance 
Wcomb 78.5% 86.0% 81.8% 
Ucomb 64.1% 81.6% 71.5% 
EPU 84.2% 84.8% 84.8% 
 
Sensitivity analysis of parameters in EPU algorithm 
We perform a sensitivity study for the parameter used in the algorithm. Parameter   
is a step size, sometimes called the learning rate in machine learning. 
To study the effect of the parameter  , we run our algorithm with   from 0.001 to 
0.03 in the scales of 0.005. The performance of the algorithm is measured on 
cardiovascular disease using three fold cross validation. Results are shown in Table 
5.5. The F-measure is relevant steady with the value of   from 0.0005 to 0.001, 
indicating that step size is small enough to move the area of minimum points in 
hypothesis space, would be helpful to find the optimal weights on error rate space. 
However, if we further increase the step size of learning rate, the algorithm 
exploration might cross the optimal (minimum) value point in hypothesis space, 
instead of staying that point, the searched large weight vector eventually affects the 
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performance of our ensemble algorithm. Nevertheless, the un-stable result in Table 
4 with   from 0.005 to 0.03 suggests that our algorithm is robust and steady when 
  becomes small. 
Table 5.5: Effect of parameter   to classification performance of cardiovascular 
disease 
Parameter   Precision Recall F-measure 
0.0005 0.852 0.810 0.840 
0.001 0.844 0.819 0.841 
0.005 0.895 0.762 0.819 
0.01 0.888 0.762 0.813 
0.015 0.894 0.743 0.804 
0.025 0.867 0.810 0.832 
0.03 0.909 0.743 0.809 
Sensitivity study of noisy data and data coverage in biological networks 
We conduct experiments to analyze how three biological networks affect disease 
gene prediction model. Table 5.6 studies the effect of the parameter k that decides 
the number of neighbors of each gene in PPI network, GO similarity network and 
gene expression similarity network. Through tuning number of neighbor 
interactions in three biological networks, EPU prediction performance is affected by 
the coverage and noisy of three biological networks. We ran EPU with k from 1 to 9 
with   = 0.001. On several disease groups like Neurological, Metabolic and 
Ophthalmological, the performance of EPU algorithm did improve with increasing 
value of k from 1 to 5, indicating that incorporating more informative similar 
neighbors is helpful for prioritizing disease genes. However, if we further include 
more neighbors (e.g. when k > 8) with low genetic similarities, noisy and 
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un-meaningful neighbors will be included and eventually affects the performance of 
disease gene prediction. For example, the results in Cardiovascular and 
Neurological disease groups showed that the performance with k = 9 has worsened. 
Nevertheless, the performance of EPU algorithm with k in wide range was 
consistently better than that of PUDI and ProDiGe, suggesting that EPU is 
insensitive to the specific value of k. 
Table 5.6: Sensitive analysis on biological network noise to disease gene prediction 
 
Disease group KNN (k) F-measure (F) 
Cardiovascular 1 84.1% 
2 83.8% 
3 82.3% 
4 82.9% 
5 82.3% 
6 82.0% 
7 82.6% 
8 82.6% 
9 82.6% 
Endocrine 
1 87.1% 
2 85.2% 
3 87.3% 
4 87.1% 
5 87.1% 
6 87.9% 
7 87.9% 
8 87.9% 
9 87.9% 
Neurological 
1 75.0% 
2 75.2% 
3 75.1% 
4 75.2% 
5 78.0% 
6 75.7% 
7 75.9% 
8 76.6% 
9 76.0% 
Metabolic 1 90/1% 
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2 89.4% 
3 89.8% 
4 90.5% 
5 90.9% 
6 90.5% 
7 90.5% 
8 90.1% 
9 89.9% 
Ophthalmological 
1 83.0% 
2 83.0% 
3 84.0% 
4 84.0% 
5 83.6% 
6 83.6% 
7 84.0% 
8 84.0% 
9 83.2% 
Cancer 
1 81.8% 
2 81.4% 
3 80.8% 
4 82.2% 
5 81.2% 
6 81.7% 
7 82.2% 
8 82.2% 
9 82.4% 
Predicting novel disease genes for disease groups 
Given a particular disease class, the set of confirmed disease genes are obtained 
from OMIM and GENECARD. Using all these disease genes as positive training set, 
we perform experiments by applying our proposed EPU algorithm to prioritize 
novel disease genes from all the unlabeled gene set. We have chosen two important 
disease groups, namely, metabolic and cancer, as a case study. 
We first applied our EPU algorithm to discover novel disease genes for metabolic 
diseases. 12 unlabeled genes are detected to be associated with target disease in our 
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algorithm. We then search literature to check whether any of these predicted disease 
genes are really related to metabolic. We found that two predicted genes, namely, 
RHEB and DOK5, have been reported to be associated with metabolic diseases. 
Particularly, Rheb, a GTP-binding protein, is inactivated to protect cardiomyocyte 
during energy deprivation via activation of autophagy. Therefore, RHEB is a key 
regulator of autophagy during myocardial ischemia, which has implications in 
patients with obesity and metabolic syndrome [146]. Tabassum et al. had identified 
that DOK5 is a novel candidate disease genes associated with type 2 diabetes, a 
metabolic disorder due to obesity [147]. From the samples in North Indian, the 
variants of DOK5 might lead to modulation of type 2 diabetes susceptibility. 
For cancer disease gene prioritization, 32 unlabeled genes are predicted as candidate 
disease genes by our EPU model. Seven of them, SIGLEC7, PRDX4, PRDX5, 
HNRNPL, SRPK1, ABCB10 and PHF10 are reported to be associated with cancer 
diseases. Table 5.7 lists these candidate disease genes and related literature evidence 
to support their association to cancer. 
For suspicious disease genes without literature evidence support, seven genes, 
PMM1, SRCIN1, ISY1, KDM4A, CIR1, PPP2R5A and NOL3, are similar 
to/interacted with confirmed cancer disease genes in terms of gene ontology, gene 
expression and protein-protein interaction. From GO similarity network, PMM1 is 
one of top 5 nearest neighbors of cancer disease gene PPM1D and SCRIN1 is one 
of neighbors of disease gene CTNNB1. In GE similarity network, ISY1 is linked to 
disease gene P2RX7, KDM4A and CIR1 are interacted with disease genes 
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CTNNB1 and MSH2 respectively, indicating that three suspicious genes are higly 
correlated with cancer disease genes in terms of gene expression. From PPI network, 
PPP2R5A is directly interacted with two disease genes, BCL2 and TP53, and NOL3 
is linking to two disease genes, BAX and CASP8. Besides the biological networks 
above, other biological knowledge can also be useful to provide insightful 
information to infer association between genes and phenotypes, such as gene 
expression and pathway. 
Table 5.7: Cancer-related genes predicted by EPU 
Gene ID Supported literatures 
SUGLEC7 Ito A. et al. (2001) Binding specificity of siglec7 to disialogangliosides of renal cell carcinoma: 
possible role of disialogangliosides in tumor progression. FEBS Lett. 
PRDX4 Lee S.U. et al. (2008) Involvement of peroxiredoxin IV in the 16alpha-hydroxyestrone-induced 
proliferation of human MCF-7 breast cancer cells. Cell Biol Int 32(4): 401-5 
Park H.J. et al. (2008) Proteomic profiling of endothelial cells in human lung cancer. J 
Proteome Res 7(3):1138-50. 
PRDX5 Enqman L. et al. (2003) Thioredoxin reductase and cancer cell growth inhibition by 
organotellurium compounds that could be selectively incorporated into tumor cells. Bioorg Med 
Chem 11(23): 5091-100. 
McNaughton M., et al. (2004) Cyclodextrin-derived diorganyl tellurides as glutathione 
peroxidase mimics and inhibitors of thioredoxin reductase and cancer cell growth. J Med Chem 
47(1): 233-9. 
Enqman L., et al. (2000) Water-soluble organotellurium compounds inhibit thioredoxin 
reductase and the growth of human cancer cells. Anticancer Drug Des. 15(5): 323-30. 
HNRNPL Goehe, R.W., et al. (2010) hnRNPL regulates the tumorigenic capacity of lung cancer 
xenografts in mice via caspase-9 pre-mRNA processing. J. Clin. Inves. 120(11): 3923. 
Hope N.R., et al. (2011) The expression profile of RNA-binding proteins in primary and 
metastatic colorectal cancer: relationship of heterogeneous nuclear ribonucleoproteins with 
prognosis. Hum Pathol. 42(3): 393-402. 
SRPK1 Hayes, G.M., et al. (2007) Serine-arginine protein kinase 1 overexpression is associated with 
tumorigenic imbalance in mitogen-activated protein kinase pathways in breast, colonic, and 
pancreatic carcinomas. Cancer Res. 67(5): 2972-80. 
ABCB10 Tang, L., et al. (2009) Exclusion of ABCB8 and ABCB10 as cancer candidate genes in acute 
myeloid leukemiaLetter to the Editor. Leukemia 23: 1000-2. 
PHF10 Wet M., et al. (2010) Preparation of PHF10 antibody and analysis of PHF10 expression gastric 
cancer tissues. Journal of Xiao Bao Yu Fen Zi Mian Yi Xue 26(9): 874-6. 
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Li C., et al. (2012) MicroRNA-409-3p regulates cell proliferation and apoptosis by targeting 
PHF10 in gastric cancer. Cancer Lett 320(2): 187-97. 
5.4 Summary 
In this work, we design a novel ensemble learning method EPU, to classify disease 
genes for different disease groups. Firstly, we extract multiple positive and negative 
samples from unlabeled set U through performing random network with restart 
algorithm on three networks, namely protein interaction network, gene expression 
similarity network, and GO similarity network. Secondly, we build three PU 
learning models independently to utilize these extracted positive and negative 
samples as training data with different confidence scores. Finally, we design a novel 
ensemble strategy EPU to integrate multiple PU learning models which can 
minimize the overall error rate and give reasonable weights to different PU learning 
models. Experimental results illustrate the effectiveness of our proposed methods. 
Our proposed EPU method performs much better than the existing state-of-the-art 
techniques for disease gene prediction. 
For further work, we will explore if there are other biological data sources are 
useful for disease gene prediction. In addition, we will integrate additional PU 
learning methods for further enhancing our EPU methods. 
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Chapter 6.  
Conclusions and Future Directions 
In this chapter, we firstly envision an overview of our research contributions 
presented in the entire Ph.D thesis, and then provide the possible directions for 
future work. 
6.1  Conclusion and Discussion 
In our research work, we focus on the protein complex network model, 
Positive-Unlabeled Learning and ensemble learning for disease gene prioritization 
and classification. In order to discover the functional modules in the protein 
complex network, we propose a three-layer heterogeneous network and investigate 
its capability for novel disease gene prediction. To discover reliable and efficient 
approaches for disease gene classification, we have applied the PU learning based 
framework PUDI and ensemble-based model EPU. 
In label propagation approach, we built a novel protein complex network by fitting 
HPRD protein interaction network and CORUM protein complexes. Our 
experimental results showed that disease genes associated with complex diseases 
can be prioritized using such a human protein complex network. We have verified 
disease gene prediction ability of the RWPCN through extensive experiments. Our 
RWPCN outperformed other existing approaches on both whole genome evaluation 
and ab initio evaluation and consistently better over different coverage of 
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phenotype interactome. As RWPCN relies on the human protein complex 
interaction network, the coverage of the protein complex data could affect 
prediction performance. Due to limited number of experimental validated protein 
complex data, predicted human protein complex with high quality and functional 
modules (such as pathway) could be taken into consideration. One possible 
improvement is to weight predicted protein complexes using protein localization, 
molecular function and biological process. Protein members within same or similar 
biological features are more likely to form protein complexes to perform biological 
functions. 
Next, a novel PU learning approach PUDI was proposed for disease gene prediction. 
Traditional machine learning methods typically build a binary classification model 
using confirmed disease genes as the positive set P and unknown genes as the 
negative set N, which may suffer from false negative samples, . Due to imbalanced 
data characteristics that only a few disease genes are identified from thousands of 
unlabeled genes on whole genome, binary classifier would lose efficacy. To address 
this issue, we propose PUDI for disease gene prediction. Assumed genes associated 
identical disease groups are more likely to form functional modules on biological 
interaction networks, PUDI first learned representative knowledge of confirmed 
disease genes, and then applied a semi-supervised learning algorithm on biological 
networks to prioritize candidate positives and reliable negatives from unlabeled 
genes. Labeling unlabeled genes with different weights, PUDI is more confident to 
build a reliable and accurate classifier for disease gene identification. Given that 
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many machine learning problems in biomedical research do involve positive and 
unlabeled data instead of negative data, we believe that the performance of machine 
learning methods for these problems can potentially be further improved by 
adopting a PU learning approach [121] [36], as we have done here for disease gene 
identification. For future work, we will consider to integrate more biological 
resources. Such as gene expression data, etc. In addition, we may explore efficient 
PU learning methods to model positive and unlabeled data distribution and address 
imbalance data issue. 
Finally we propose an ensemble-based framework, namely EPU, to prioritize 
disease genes associated with six disease classes. By using multiple biological data 
sources, EPU is less susceptible to potential bias, incompleteness and noise in single 
data source. By employing an ensemble approach for prediction, EPU also 
minimizes the inherent limitations of single learning models. However, ensemble 
learning model works when component data sources/ learning classifiers are 
independent, unrelated and complementary. Since correlated components are likely 
to make similar decisions, ensemble framework with correlated components tends 
to build a bias classifier. One possible improvement of our work is to reduce highly 
correlated learning models from the ensemble learning framework and retain 
complementary and reliable learning models. For future work, we will consider 
other methods to search for global optimal points on error spaces more efficiently, 
like the Markov chain Monte Carlo (MCMC) method. On the other side, we may 
explore better machine learning methods to combine multiple data sources with 
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different data distributions. 
6.2  Future Directions 
Here we provide several possible directions for future study in the area of disease 
gene prediction. 
6.2.1  Integration of more biological interactions to improve 
protein complex interaction network  
In this thesis, we propose a three-layer network model (RWPCN) for disease genes 
prediction. However, the protein complex data is extracted from CORUM, which 
contains only part of the existing human protein complexes [78]. We did not 
consider the high-quality protein complexes obtained from the computational 
approaches. Another problem is that we measure the strength of protein complex 
interactions using only PPI data, which has a high false-positive rate. Integration of 
more biological interactions might increase the quality of protein complex 
interactions. A possible direction for modeling a reliable protein complex network 
is to extend protein complexes using reliable protein complexes detected by 
computational approaches [99]. Another improvement is to evaluate protein 
complex interaction using diverse biological evidences (e.g. biological process, 
gene expression profiles [148] and metabolic reactions [149]). 
6.2.2  Phenotype Entities Similarity Calculation 
The phenotype similarity could also be improved. In this thesis, the similarity 
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between two phenotype entities is calculated based on the text description in OMIM 
[81]. To calculate the similarity of phenotypes, they used OMIM Mesh terms 
instead of a controlled vocabulary [74]. Recently, the Human Phenotype Ontology 
(HPO) has been proposed [53]. HPO provides a standard vocabulary to describe 
phenotypic abnormalities in human diseases, such as atrial septal defect. However, 
different phenotype data sources have different predictive power for different 
diseases due to the data characteristics and quality. It is necessary to balance the 
phenotype similarities, according to the prediction performance on different disease 
classes. With the availability of well annotated phenotype data and accurate 
similarity measurements, a better quality phenotype network could be obtained to 
improve the prediction ability of our method. 
6.2.3  Improving the network propagation based method (RWPCN) 
using machine learning based classification approaches 
We want to explore how to integrate the network propagation based method 
(RWPCN) with other machine learning based classification methods. Given the 
different characteristics of two methods, we could minimize the potential bias and 
risk of each individual method and thus further improve the prediction accuracy. 
Classification methods, such as SVM and Neuron network, can assign weights to 
test examples, which represent a kind of similarity to positive or negative class, just 
like the scores assigned by Random Walk with Restart to nodes based on 
topological similarity to initial labeled nodes on the networks. Both continuous 
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outputs provided by the machine learning and network propagation approaches are 
interpreted as the degree of support given to that class (such as disease class and 
non-disease class). Classifier fusion [150] is a method that provides a strategy for 
combining the outputs generated by individual approaches. In this method, classifier 
outputs are normalized to the [0, 1] interval, allowing formation of an ensemble 
through algebraic combination rules, such as majority voting, 
maximum/minimum/sum/product [151] [152] [153] and kernel method [154] [155]. 
6.2.4  Prioritization of loci using GWAS data 
Recently, many scientific teams have been examining the genomes of thousands of 
people in an attempt to find mutations presented only in individuals with certain 
traits. Interactions amongst genome loci associated with diseases have been largely 
mapped from data generated through forward genetic approaches, such as 
recombination hotspot [156] [157] [158] [159] [160], genome-wide linkage [161] or 
genome-wide association studies (GWAS) [162] [163]. Such methods leverage 
naturally occurring mutations in the genome to pinpoint loci that have associations, 
ideally causal associations, with a trait of interest [164]. 
6.3  Final Remarks 
Identifying disease genes from the human genome is a crucial but challenging task 
in the area of bioinformatics research and medical health. In wet-lab experiments, 
disease genes are identified using mutation analysis, which is very expensive and 
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labor intensive. In this thesis, we proposed novel computational approaches to 
prioritize and identify disease genes. The experimental results show that our work is 
more robust and accurate than other state-of-the-the-art techniques for disease gene 
identification.  
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